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Abstract 
Epidermal growth factor (EGF) is important in the regulation of proliferation in 
hepatocytes. The receptor for EGF belongs to the receptor tyrosine kinase family, and 
activates different intracellular signaling proteins by tyrosine phosphorylation. The EGF 
receptor can activate several signaling pathways, and their role in growth regulation has 
been extensively studied. But the molecular mechanisms that modulate the different 
signaling pathways are not clear. This study focuses on the regulation of STAT signaling 
by the EGF receptor, and particularly the involvement of Stat5b in growth control in 
hepatocytes. We found that the EGF receptor activated Stat5b by phosphorylation on 
residue Tyr-699 and other sites, but it was the Tyr-699 phosphorylation that correlated 
with the DNA binding activity. This activation was dependent of the non-receptor 
tyrosine kinsase Src, but Stat5b activation by other growth factors was not. Furthermore, 
the EGF induced Stat5b activation was downregulated in mitogenically responsive 
hepatocytes, and provides more evidence against Stat5b involvement in mitogenic 
signaling from the EGF receptor in hepatocytes. In addition we examined the mechanism 
behind the comitogenic effect of G protein coupled receptor (GPCR) ligands on EGF 
induced growth. Vasopressin, norephenephrine, angiotensin II, and prostaglandin F2α are 
such ligands, and they acts as comitogens in hepatocytes. We found that in hepatocytes 
GPCR ligands did not transactivate the EGF receptor, but rather regulated the 
transcription of early response genes c-Myc and ATF3. 
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The Role of Epidermal Growth Factor Receptor Mediated 
Signaling in Mitogenic Activation of Hepatocytes. 
General purpose of this study 
This study concentrates on the activation and intracellular signaling from the EGF 
receptor in the regulation of cellular proliferation, using hepatocytes in primary cultures 
as a model. Activated EGF receptor can use various intracellular signaling pathways, but 
how the receptor regulates its signaling cascades to induce cell growth is unclear. Insight 
into these molecular mechanisms and pathways is important for understanding normal 
and pathological cell growth, and may give us potential targets for pharmacological 
interference. Cancer is a disease where control of cellular signaling is lost, resulting in 
uncontrolled proliferation.    
Introduction 
Cell-division cycle  
Cells reproduce by dividing into two 
after duplicating their contents. The 
sequence of events leading to cell 
division is called the cell cycle, which 
consists of different phases (see fig. 1). 
Most cells in an adult body are in a 
resting state, the G0 phase, and are not 
active dividing. In the G0 phase the 
cells are performing specialized 
functions while they are under strict 
control mechanisms that inhibit their 
ability to proliferate (van der Geer et al., 1994; Schlessinger, 2000). To exit the G0 phase 
and progress into the cell cycle, cells are dependent upon stimulatory signals (O'Farrell, 
1992). Growth factors are peptides that may act as such signals. They can stimulate the 
S
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Figure 1: The Cell cycle 
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cell to advance into the G1 phase and enter S phase followed by cell division. On the 
contrary, other peptides can be inhibitory and holdback the advancement in the cell cycle.  
The passage through the restriction point and entry into S phase is controlled by 
cyclin-dependent protein kinases (Cdk), which themselves are regulated by cyclins and 
Cdk inhibitors. An example is the phosphorylation of the retinoblastoma tumor 
suppressor protein (RB) by cycline-D1 Cdk’s, which in many cell systems is required for 
entry to S phase (Sherr, 1996).  
Growth factors and receptor tyrosine kinases 
Growth factors are polypeptides that regulate cellular proliferation, but they may have a 
number of other effects. They function largely in a paracrine or autocrine fashion, and 
exert their actions by binding to and activating specific receptors. Activation of receptors 
is the first step in a series of intracellular events leading to regulation of the cell cycle 
machinery or other functions (van der Geer et al., 1994). 
One group of receptors is membrane spanning cell surface receptors, which can 
be classified by their biological action. A large family is receptors which have intrinsic 
protein tyrosine kinase activity, so called receptor tyrosine kinases (RTK) (Schlessinger, 
2000). In this family we find the receptors for growth factors like epidermal growth 
factor, which was the first to be discovered, and platlet derived growth factor (PDGF). 
The EGF receptor has been extensively studied as model for intracellular signaling in the 
regulation of proliferation. Also in this family is the receptor for insulin, which 
traditionally is not classified as a growth factor, but has many and complex effects on 
growth in hepatocytes (Christoffersen et al., 2000).  
EGF receptor and agonists 
The EGF (EGFR = ErbB1 = HER1) receptor belongs to the receptor tyrosinkinase 
familiy (RTK) (Carpenter and Cohen, 1990; Schlessinger, 2000). Together with Erb2, 
Erb3 and Erb4 (HER1 to HER 4) they constitute the HER/ErbB superfamily (Prenzel et 
al., 2001). The EGF receptor (Mw=170 000) is composed of a single polypeptide chain, 
containing 1 186 aminoacids, and with approximately 40 kDa N-coupled 
oligosaccharides extracellularly. It has an extracellular ligand binding domain and an 
intracellular domain witch contains the tyrosine kinase and the different tyrosine residues 
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that act as docking sites for signaling proteins 
when phosphorylated (fig. 2). Between the 
extra- and intracellular domain is a 
hydrophobic transmembranal part, and a 
intracellular juxtamembranal domain 
(Carpenter and Cohen, 1990).  
 EGF it is a 6.0 kDa (53 aminoacids) 
heatstable polypeptide, which along with NGF 
was the first growth factor to be characterized 
(Savage et al., 1972). Since then a large 
number of EGF receptor and receptor family 
ligands have been described (see table 1). 
Common for all is that they are derived from 
transmembrane precursors that are cleaved to 
give rise to soluble ligands. They can be 
divided into three classes depending on their 
binding specificities. One group includes EGF itself, transforming growth factor alpha 
(TGFα), amphiregulin (AR), and epigen (Savage et al., 1972; Beerli and Hynes, 1996; 
Harris et al., 2003). Each of these ligands can all bind the EGF receptor (ErbB1), and 
they all compete for binding to the receptor. Another class contains the ligands that bind 
ErbB4 in addition to the EGF receptor, and here we find the ligands betacellulin, heparin-
binding EGF (HB-EGF), and epiregulin. The last class of EGF-related peptides is 
composed of neu differentiation factors (NDFs)/heregulines (Holmes et al., 1992), which 
are ligands for ErbB3 and ErbB4 (Plowman et al., 1993; Carraway et al., 1994). ErbB2 
has no known ligand yet, and function by heterodimerization with other EGF receptor 
family members (Olayioye et al., 2000; Holbro and Hynes, 2004). 
When a ligand binds to the EGF receptor it leads to dimerization of two receptors 
and activation of the intrinsic tyrosin kinase. The dimerization can either be 
homodimerizaton of two receptors of same type or a hetero dimerization of two different 
members of the EGF receptor family. An example is that EGF can induce tyrosine 
phosphorylation of ErB2 through formation of heterodimers of ErbB1 and ErbB2 (King 
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Figure 2: EGF receptor homodimer. 
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et al., 1988). Heterodimerization adds an additional level of complexity in signaling from 
the EGF receptor.  
EGF and TGFα both bind and activate the EGF receptor, however certain 
differences in their biological functions have been shown. In some cells TGFα is more 
efficient than EGF, and gives a stronger biological respons. This is shown in hepatocytes 
after stimulation with EGF or TGFα, where TGFα gives a stronger growth respons than 
EGF (Guren et al., 1996). The mechanisms behind this difference are unknown. 
Table 1. EGF receptor and HER family agonists 
(Harris et al., 2003) 
Receptor 
Epidermal growth factor (EGF) EGF receptor 
Transforming growth factor (TGFα) EGF receptor 
Amphiregulin (AR) EGF receptor 
Epigen EGF receptor 
Heparin-bining EGF-like growth factor EGF receptor/ErbB4 
Epiregulin (EPR) EGF receptor/ErbB4 
Betacellulin (BTC) EGF receptor/ErbB4 
Cripto EGF receptor/ErbB4 
Neuregulin-1 (NRG-1) ErbB3/ErbB4 
Neuregulin-2 (NRG-2) ErbB3/ErbB4 
Neuregulin-3 (NRG-3) ErbB4 
Neuregulin-4 (NRG-4) ErbB4 
 
Intracellular signaling from the EGF 
receptor 
Ligand binding to the EGF receptors induces 
dimerization of two receptor, heterodimers or 
homodimers. Dimerazation leads to proximity 
of two cytoplasmic tyrosine kinase domains; 
this allows autophosphorylation of the dimeric 
partner. Autophosphorylation causes both 
increased kinase activity by a phosphorylation 
in the activation loop of the catalytic domain, 
and phosphorylation of a number non-catalytic 
sites on the receptor. The tyrosine 
phosphorylation sites of the non catalytic JunK
Sos
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MEK
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P
P
P
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P
P
P
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Figure 3: Potential signaling pathways 
from the EGF receptor 
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residues of the cytoplasmic domain may serve as docking sites for signaling proteins that 
bind phosphotyrosine or specific protein regions, thus coupling the receptor to various 
intracellular signaling pathways (Schlessinger, 2000). Signaling proteins involved have 
specialized domains for recognition of phosphotyrosine: Src homology-2 (SH2) domains 
and phosphotyrosine binding (PTB) domains binds to tyrosine phosphorylated residues. 
In addition, SH3 domains that bind proline rich sequences on proteins have been 
described (Koch et al., 1991; van der Geer and Pawson, 1995). It has been shown that the 
EGF receptor has several potential substrates that may represent potential pathways, and 
the role of the different pathways in mitogenic signaling has been extensively studied.   
 
Mitogen Activaded Protein Kinase (MAPK) pathway 
MAPKs are important components in intracellular signaling, in particular in mitogenic 
signaling (Lewis et al., 1998). In hepatocytes the EGF receptor activates MAPKs of the 
Erk1/Erk2 subtypes, and the extent of the sustained ERK activation in mid/late G1 phase 
correlates with the degree of stimulation of DNA synthesis/cellular proliferation 
(Thoresen et al., 1998). EGF receptor activates Erk1/Erk2 by recruiting Shc and/or Grb2 
to the receptor, Shc and Grb2 have no kinase activity themselves. They are adapter 
proteins which allow the recruitment of the Grb2/Sos complex under the membrane.  Sos, 
the exchange factor of Ras, is then able to activate Ras by facilitate the exchange of GDP 
for GTP. Activated Ras recruit Raf which activates MEK that phosphorylates Erk1/Erk2 
on both threonine and tyrosine residues (Schlessinger, 2000). Activated Erk1/Erk2 is 
rapidly translocated into the nucleus where it phosphorylates and regulates several 
transcription factors, including proto-oncogenes c-Fos, and c-Myc (Lewis et al., 1998; 
Hunter, 2000).  
Shc an adapter coupling the EGF receptor to MAPK pathway 
Shc is an adapter protein that contains an N-terminal PTB domain, a C-terminal SH2 
domain, and a central collagen-like region that contains three tyrosine phosphorylation 
sites (Koch et al., 1991; Pelicci et al., 1992; van der Geer and Pawson, 1995). In 
mammals three shc genes have been described, their products are referred to as ShcA, 
ShcB, and ShcC. ShcB and ShcC seem to be limited to neuronal cells in mammals, but 
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ShcA is ubqiuitously expressed (Pelicci et al., 1996; Ravichandran, 2001). ShcA is 
expressed as three isoforms, possibly generated through either RNA splicing or 
alternative translation initiation (Pelicci et al., 1992). The three isforms have different 
molecular weight of about 46, 52, and 66 kDa, but they are recognized with the same 
antibody (Ravichandran, 2001). The 52 and 46 kDa isoforms are shown to couple growth 
factor receptors to the MAPK pathway (Ravichandran, 2001), and is the 52 kDa isoform 
that is predominantly activated in hepatocytes (data from our lab). The function of the 
last isoform is more uncertain, but it has been proposed to be a negative regulator the 
MAPK pathway (Okada et al., 1997).   
 Shc is activated by tyrosine phosphorylation, and then Grb2 interacts with Shc by 
a SH2 domain. As described earlier, Grb2 activates MAPK pathway by recruiting Sos to 
the cell membrane, therefore Shc is coupling the EGF receptor to the MAPK pathway 
(Schlessinger, 2000).   
Signal Transducers and Activators of Transcription (STAT) 
The STAT family of signaling proteins is activated by tyrosine phosphorylation, whereby 
they dimerize and translocate into the nucleus. In the nucleus they bind directly to 
promoter regions of specific genes and regulate their transcription (Darnell, 1997; 
Schlessinger, 2000). Nine different STAT proteins have been described in mammals, 
transcribed from six genes, denoted as Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6. 
The proteins are named as the genes, and in addition Stat1β- and Stat3β-proteins are 
occurring as alternative splice variants of the respective gene (Bowman et al., 2000). 
They were first described as mediators for the actions of interferons and other cytokines 
(Ihle, 2001), but STAT proteins have also been implicated in signaling from growth 
factor receptors (Leaman et al., 1996).  
Intraperitoneal injection of EGF has been shown to activate Stat1, Stat3, Stat5a 
and Stat5b in mouse liver (Ruff-Jamison et al., 1993), indicating a role in signaling from 
the EGF receptor. Previous studies in our laboratory showed that in freshly isolated rat 
hepatocytes, Stat1, Stat3, and particularly Stat5b are activated by EGF. The ability of 
EGF to induce this activation was attenuated during culturing, while cytokines retained 
their ability to activate Stat1 and Stat3 (Guren et al., 1999). Src tyrosin kinases have been 
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implicated in EGF receptor-mediated activation of Stat3 and Stat5 (Olayioye et al., 1999; 
Wang et al., 1999). 
c-Src and signaling from the EGF receptor 
The Src family of kinases is intracellular non-receptor tyrosine kinases. A viral form of 
one of the Src protein tyrosin kinases, namely v-Src from the Rous sarcoma virus, was 
the first recognized and transforming protein (oncogene). The cellular form of the 
mutated v-Src is known as c-Src. Both v-Src and c-Src have intrinsic tyrosine kinase 
acitivity. The Src family of tyrosine kinases comprise of Lck, Blk, Fgr, Lyn, and Hck 
which are expressed preferentially in hematopoietic cells, while the three c-Src, Fyn, and 
Yes are more generally expressed. They have been shown to regulate numerous and 
pleiotropic effects in cells, like cytoskeletal alterations, differentiation, survival, 
adhesion, and migration (Thomas and Brugge, 1997; Frame, 2002).  
The protein structures of the different members of the Src family shows 
similarities. c-Src is a 60kDa membrane-anchored intracellular protein tyrosine kinase, it 
is composed of six functional regions: SH4 domain (membrane localizing signal), a 
unique region (differs between the family members), SH3 domain, SH2 domain, and a 
catalytic domain. SH3 and SH2 domains are partly responsible for the regulation of the 
enzymatic activity of c-Src, especially the interaction of the SH2 domain and the 
phosphorylated tyrosine residue, Y527. When c-Src is phosphorylated on the C-terminal 
Y527, the SH2-Y527 interaction folds the protein into a less active conformation. 
Dephosphorylation of Y527 and autophorylation of the Y416 residue in the activation 
loop of the catalytic domain is essential for full activity of c-Src tyrosine kinase (Thomas 
and Brugge, 1997).  
Many RTKs can recruit and activate Src family kinases, and residues on RTK can 
themselves be substrates for the Src kinases (Thomas and Brugge, 1997). Thus, Src 
kinases can theoretically regulate both receptors themselves and downstream signaling 
proteins. c-Src has been shown to be essential for PDGF induced mitogenesis in some 
cells (Twamley-Stein et al., 1993). In addition, it has been shown to phosphorylate the 
EGF receptor on specific tyrosine sites, but c-Src role in mitogenic signaling from the 
receptor is unclear (Biscardi et al., 1999).  
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Phosphoinositol-3-kinase  
Phosphoinositol 3-kinase (PI 3-K) is activated when binding to p85, an adopter protein 
containing two SH2 domains and one SH3 domain in addition to the binding site for PI 3-
K. p85 couples PI 3-K to receptor tyrosine kinases, and are reported to be phosphorylated 
in some cell models. But the mechanism leading to activation is not fully understood. 
PI 3-K is activated by a number of RTK, but its role in EGF receptor mediated 
mitogenic signaling has been uncertain (Hu et al., 1992; Raffioni and Bradshaw, 1992). 
Newer data suggest that it can mediate growth response independently, and it has been 
shown that inhibitors of PI3K completely blocks EGF induced proliferation (Band et al., 
1999; Thoresen et al., 2003). This suggest a mechanism where PI 3-K acts together with 
ERKs to stimulate growth. 
Phospholipase C gamma (PLC-γ) 
PLC-γ is a major target for many RTKs (van der Geer et al., 1994), and it can probably 
bind Tyr-922 and Tyr-1173 on the C-terminal site of the EGF receptor. Its role in EGF 
receptor signaling is unclear. In hepatocytes, which express a high level of PLC-γ, there 
is little evidence for EGF receptor induced activation of PLC-γ (Dajani et al., 1999). 
G protein-coupled receptors (GPRCs) 
GPRCs are receptors coupled to heterotrimeric GTP-binding proteins (G-proteins), and 
are large family of cell surface receptors characterized by their seven transmebrane 
domains joined by intracellular and extracellular loops (Ji et al., 1998). GPRCs are 
coupled to G-proteins which consist of three subunits, Gα,Gβ,and Gγ, which is stably 
associated when bound to GDP. Ligand binding to the receptors leads to exchange of 
GDP for GTP in the α-subunit, and the Gβγ dissosates from the GTP-Gα (Hamm and 
Gilchrist, 1996). Both Gβγ and Gα can mediate cellular effects bye interacting with other 
proteins. G-proteins are classified by the type of Gα subunit: Gs stimulate adenelyl 
cyclase and the production of cAMP, and Gi/o mediates inhibition of adnelyl cyclase and 
inactivition of ion channels. Gq is known til couple receptors to activation of PLC-
isoforms. The function of Gβγ-subunit is unclear, but regulation of various kinases and 
cyclases has been shown (van Biesen et al., 1996). 
 12
There is evidence that ligands that bind GPRCs can influence cellular 
proliferation, and GPCR agonists like norephenephrine, vasopressin, angiotensin II, and 
prostaglandin F2α have in hepatocytes co-mitogenic effects on EGF receptor mediated 
cellular growth (Dajani et al., 1996; Thoresen et al., 1999). These agonists are mainly 
thought to act on Gq-coupled GPRCs. A part of this study has explored the underlying 
signaling mechanism behind the interaction between GPRCs and the EGF-receptor. 
Interaction between EGF receptor and GPCRs signaling: 
The mitogenic signal from EGF can be modulated by agonists that use GPCRs.  
GPCR ligands may have co-mitogenic effects on EGF receptor mediated DNA synthesis, 
but others may have growth inhibitory effects. Co-mitogens are growth factors witch are 
consider to have no or little mitogenic effect alone, but together with complete mitogens, 
like EGF and TGFα, they promote cellular proliferation (Michalopoulos, 1990; Thoresen 
et al., 1990). Angtiotensin II, norephenephrine, vasopressin, and prostaglandin F2α acts as 
co-mitogens in hepatocytes in primary cultures (Refsnes et al., 1992; Refsnes et al., 
1994). There are proposed several theories on the mechanisms behind comitogens; for 
example crosstalk between intracellular signaling pathways, or regulation on the level of 
gene transcription. 
Cross talk between GPRC and the EGF receptor 
The signaling pathways from RTK to Erk1/2 are, as described, well known. It has been 
shown that various GPCR ligands can induce activation of Erk1/Erk2 (Zwick et al., 
1999), but the mechanism behind this cross-talk between the signaling systems is only 
partly clear. This has received increasing interest in recent years, and several mechanisms 
have been proposed.  
Transactivation of the EGF receptor 
It has been found in some cells that GPCR ligands rapidly induce tyrosine 
phosphorylation of the EGF receptor and activation of downstream signaling pathway 
leading to Erks (Daub et al., 1997; Zwick et al., 1999). This is an example of cross-talk 
between the different pathways that provides more diversity in the signaling from the 
EGF receptor. The mechanism behind GPCR-induced activation of the EGF receptor is 
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incompletely understood, but the kinetics of EGF transactivation is rapid suggesting 
involvement of either a tyrosine kinases or increased activity of the EGF receptor kinase 
itself (Daub et al., 1997; Holbro and Hynes, 2004). The cytoplasmic domain of the EGF 
recptor has been shown to be phosphorylated by the tyrosine kinases c-Src and Janus 
kinase 2 (Jak2), thus providing sites for intracellular signaling proteins (Yamauchi et al., 
1997; Biscardi et al., 1999). The sites act as scaffolds for the tyrosine kinases, which can 
activate downstream signaling without the EGF receptor kinase (Holbro and Hynes, 
2004). Another theory suggests that EGF receptor transactivation upon GPCR stimulation 
involve the EGF receptor tyrosine kinase itself. The EGF receptor is stimulated by the 
autocrine release of EGF receptor ligands, which is mediated by a metalloproteinase 
activity that is rapidly induced by GPCR ligand interaction. Activity of the 
metalloproteinase leads to the cleavage of membrane-bound pro-EGF receptor ligands 
that activate the EGF receptor, resulting in phosphorylation of downstream signaling 
proteins and activation of Erk (Prenzel et al., 1999). The mechanism of GPCRs induced 
activation of the metalloproteinase is not known.   
Regulation of gene expression 
Much of the cellular signaling results in regulation of gene transcription, by activation or 
deregulation of transcription factors. Transcription factors associated with growth 
regulates the expression of genes responsible for cell cycle progression (O'Farrell, 1992). 
Expression of transcription factors and proto-oncogenes c-Myc, c-Fos, and c-Mos have 
been shown to be increased after stimulation with GPCR ligands in hepatocytes,  
(Gonzalez-Espinosa and Garcia-Sainz, 1992).  
Hepatocytes as a model system 
Primary cultures of hepatocytes are useful as a model in the study of regulation of 
cellular proliferation. Freshly isolated hepatocytes are normal cells with intact receptors 
and signaling transduction pathways, as opposed to cells that are transformed or 
transfected. Thus, the hepatocytes may provide experimental information of signal 
transduction and normal regulation of proliferation which is a useful complement to data 
obtained in genetically manipulated cells. Also, hepatocytes can be cultured in a serum-
free, chemically defined medium (Sand and Christoffersen, 1988), which is important 
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while serum can contain undefined hormones and growth factors that may influence the 
regulation of cellular proliferation (Christoffersen et al., 2000). 
 
Hepatocytes as a G0/1 to S phase model 
Hepatocytes are mainly in early G1 or in transition from G0 to G1 when they are plated. 
During the next 24 to 48, the cultured hepatocytes progress through the early part of G1. 
This may happen independently of growth factors, but the process is dependent on 
insulin. Insulin is also required for growth responses after exposure to mitogenic growth 
factors, this effect is mainly evident in early G1 (Sand et al., 1985). Some ligands that 
uses GPCRs, for example glucagons, adrenergic agonists, vasopressin, angiotensin II, and 
prostaglandins, acts as co-mitogens in hepatocytes. They appear to exert their effect by 
accelerating the traverse through G1, and thus make more cells responsive to EGF (or 
other EGF receptor agonists) in mid/late G1, near the restriction point for further progress 
and descion to enter S-phase (Pardee, 1989; Michalopoulos, 1990; O'Farrell, 1992). EGF 
receptor ligands seem to exert their effect in mid/late in G1 (Sand and Christoffersen, 
1987; Loyer et al., 1996; Talarmin et al., 1999).  
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Figure 3: Hepatocytes as a model system 
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Aims of the study 
Stimulation of the EGF receptor mediates growth of hepatocytes by activation of 
different intracellular signaling pathways, but the mechanisms that regulate these 
pathways are unclear. This study concerns the activation and regulation of pathways from 
the EGF receptor, and the interaction between EGF receptors and various GPCR ligands 
signaling pathways.  
More specifically, the study focused on:  
 
1. The mechanisms of EGF receptor mediated activation of STAT proteins, 
particularly the regulation of Stat5b activation. And Stat5b’s role in mitogenic 
signaling from the EGF receptor.  
 
2. The role of EGF receptor transactivation in the signaling mechanisms involved in 
growth stimulatory effects of GPRC ligands.  
Papers 
Two papers are included in this thesis; they are referred to by the numbers they are listed 
here: 
I. Guren T. K., Ødegård J., Abrahamsen H., Thoresen G. H., Susa M., Andersson Y., 
Ostby E., Christoffersen T. EGF receptor-mediated, c-Src-dependent, activation of 
Stat5b is downregulated in mitogenically responsive hepatocytes. J Cell Physiol. 2003 
Jul;196(1):113-23. 
 
II. Nilsen, L. S., Ødegård J., Thoresen, G.H., Molven, A., Sandnes, D. and 
Christoffersen T. G protein-coupled receptor agonists stimulate expression of 
ATF/LRF-1 and c-myc and exert comitogenic effects in hepatocytes without inducing 
EGF receptor transactivation. J Cell Physiol. 2004. Accepted. 
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Methods 
Isolation and culture of hepatocytes 
Male Wistar Rats were fed ad libitum. Hepatocytes were isolated by in vitro collagenase perfusion and low 
speed sentrifugation (Seglen, 1976) with modifications (Christoffersen et al., 1984). The hepatocytes were 
seeded onto Costar plastic flask or culture wells depending on the experiment, at cell density of 20 000 per 
cm2 to 50 000 cm2. The culture medium was a serum-free 1:1 combination of Williams’s E medium and 
Dulbecco’s modified Eagle’s medium with collagen (3 µg/ml), 100 nM insulin, and 25 nM dexamethasone. 
The medium were supplemented with penicillin (67 µg/ml) and streptomycin (100 µg/ml). The cultures 
were kept in 95% air/5% CO2 at 37 ˚C. 
Measurement of DNA synthesis 
[3H] Thymidine was added to the cultures (1 µCi/ml, 0.125 Ci/mmol) at 24 and 48 hour after plating. Cells 
were lysed with 0.5 M NaOH at 52 or 72 hours after plating, and DNA was precipitated with 
trichloricaceticacid before filtration. DNA synthesis was assed by determing the amount of radioactivity 
cumulatively incorporated into DNA (Refsnes et al., 1994). Protein was determined using Coamassie Plus 
Protein Assay (Pierce, Rockford, IL, USA). 
Immunoprecipitation 
The method is based on previously described methods (Yamashita et al., 1998). After agonist stimulation 
the plated cells were rapidly rinsed twice in ice cold 0.9% NaCl, and once in immunoprecipitation (IP) 
buffer A (50 mM  Tris-HCl, pH 7.4, 280 mM NaCl, 0.2 mM EDTA, 2.0 mM EGTA, 10% glycerol, 1 mM 
activated Na3VO4, 50 mM Na4P2O7, 1 mM phenylmetylsulfonyl fluoride (PMSF), and Complete protease 
inhibitor (Boehringer Mannheim, Germany)). Cells were lysed in 1 ml IP buffer A ,supplied with Nonidet 
P-40 (NP-40) to final concentration 1%, for 15 min on ice and the lysates were transferred into Eppendorf 
tubes. Insoluble material was pelleted at 13000 rpm for 10 min at 4 ˚C. Depending on the experiment, 
clarified lysates (approximately 250 µg protein) were incubated for 60 min with rabbit polyclonal 
antibodies and the complexes were captured with Dynabeads® (Dynal AS, Oslo, Norway) 0.25 mg per 
extract, coated with sheep anti-rabbit antibodies (a gift from dr. Kjell Nustad, The Norwegian Radium 
Hospital, Oslo, Norway). Complexes were washed three times with IP buffer A with 0.5 %  NP-40. 
 Shc proteins were immunoprecipitated under denaturating conditions. After agonist stimulation 
the cells were lysed inn 500 µl lysis buffer (10 mM Tris-HCl, pH 7.4, 1 % SDS, 1 mM Na3VO4), that was 
boiling when added, then the lysates were boiled for 5 min. After 3 passages through a 27 x G gauge on ice, 
the lysates were cleared by centrifugation (10 min, 13000 rpm at 4 ˚C). 250 µg of lysate was incubated 2 
hours in IP-buffer B (10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 1 mM EGTA, 0.2 mM  
Na3VO4, 0.2 mM PMSF, 0.5 % NP-40 and 1 % Triton-X100) with phosphotyrosine antibody PY-99 (Santa 
Cruz Biotechnology). The immune complexes were captured with Dynabeads® M-280 sheep anti-Mouse 
IgG overnight at 4 ˚C, and washed three times with ice-cold IP-buffer B. 
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 The proteins were released from the Dynabeads® by boiling for 5 min in 2x Laemmeli sample 
buffer. Immunoprecipitates were separated in 8-12%, depending on protein weight, SDS-PAGE gels.  
Immunoblotting 
Immunopreciptates or aliquots of 20 µg cell protein (prepared in Laemmeli buffer) were separated in 8-
12%, depending on protein weight, polyacrylamid (30:1 acrylamide: N’N’-bis-acrylamide) gel 
electrophoresis (PAGE), then transferred to nitrocellulose membranes. Membranes were blocked in T-TBS 
(10 mM Tris-HCl, pH 8.0, 150 mM NaCl) with 5% low fat dry milk and 0.05% Tween 20 or T-TBS with 
1% bovine serum albumine (BSA) for detection with RC-20 antibody, for 45 minutes, followed by 
incubation over night at 4 ˚C with primary antibodies. The secondary antibodies, sheep anti-rabbit or anti-
mouse IgG antibodies conjugated to horseradish peroxidase, were incubated in blocking solution for 1.5 
hours. The blots were washed in T-TBS for 15 minutes times 3 and then rinsed in water, before they were 
visualized with Enzyme-linked Chemiluminescence Reagent (ECL, Amersham Pharmacia). Densiometric 
analysis of immunoblots was obtained with Labworks Software (UVP, Cambridge, UK). Membranes were 
blocked and reprobed with another antibody after they were washed in H2O and stripped in 0.5 M NaOH. 
Electrophoretic mobility-shift assay (EMSA) 
Oligonucleotide probes: Singlestranded oligionucleotides were synthesized at the Biotechnology Center of 
Oslo, University of Oslo, Norway. Sequence used: 5’-GGA CTT CTT GGA ATT AAG GGA-3’, which 
contains prolactin inducible element (PIE) of the rat β-casein gene and binds Stat5 and Stat1 (Wakao et al., 
1994). The oligonucletides were end-labeled using [γ-32P] ATP and 14 polynucleotide kinase (New 
England Biolabs, Beverly, MA, USA), followed bye annealing to the complementary oligonucleotide 
sequence to get double-stranded probes.  Probes were purified through a 12% non-denaturated PAGE in 0.5 
x TBE (89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA). The band corresponding to the double stranded 
probes was detected by autoradiography, cut out of the gel, and eluted in 0.1 x TE-buffer (10 mM Tris-HCl 
pH 7.5, 1 mM EDTA) over night. 90% of the water in the eluate was removed by 2-butanol extraction, and 
the oligonucleotides were stored in 1 x TE buffer in final concentration of 20 fmol/µl. The specific activity 
of the probes were 5-6000 cpm/fmol. 
Preparation of nuclear extracts from cultured hepatocytes:  Nuclear extracts were prepared, by a slightly 
modified version of methods developed for cultured cells (Schreiber et al., 1989; Sadowski and Gilman, 
1993). In brief, hepatocytes in primary culture were rapidly washed, and kept on ice for lysis in 1 ml 
hypotonic buffer A, containing 20 mM HEPES, pH 7.9, 10 mM KCl, 10% glycerol, 1 mM EDTA, 1mM 
EGTA, 20 mM NaF, 1 mM Na4P2O7, 0.1 mM Na3VO4, 50 µM Na2MnO4, 1 mM DTT, and Complete 
Protease Inhibitor (1 tablett per 50 ml solution) for 15 minutes. The cells were scraped with a rubber 
policeman and collected. Nonidet P-40 was added to the lysates to concentration of 0.20%, then wortexing 
for 15 sec. The nuclei were pelleted by centrifugation at 10 000g for 30 seconds, and the nuclear pellet was 
resuspended in 100 µl of a high salt extraction buffer C (buffer A with addition of 420 mM NaCl), under 
gentle rocking for 30 min.  
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EMSA: 10 µg of nuclear extracts were preincubated with a binding buffer (13 mM HEPES, pH 7.9, 80 mM 
NaCl, 8% glycerol, 0.15 mM EDTA, and 1 mM dithioreitol) in presence of 3 µg double stranded poly(dI-
dC) (Amersam Biosciences, Buckinghamshire, UK). 1 µl 32P-labeled probe was added to a total volume of 
20 µl, and incubated for 30 minutes. Supershift analysis was done by including high-titered polyclonal 
antibodies against Stat5a, Stat5b or polyclonal Transcruz antibodies against Stat1 (Santa Cruz 
Biotechnologies) for further 30 minutes, before addition of labeled probes. 10 µl of incubated DNA-protein 
complexes were loaded on 5% non-denaturated PAGE in 0.5% TBE and electrophorezed at 210 V. The 
gels were dried and visualized by autoradiography. 
Results 
Paper I 
The first paper is based on the work done in cooperation with Guren T.K. and others, I 
looked into the mechanisms of EGF recptor induced activation of Stat5, and the 
significance of this signaling mediator in EGF induced mitogenesis. My main 
contributions in this paper were the results showing the activation of Stat5b by general 
and site specific phosphorylation, after stimulation with EGF and other growth factors. I 
also looked into ligand induced activation of the EGF receptor and the downstream 
signaling component Shc, and the expression of cycline D1 after stimulation with EGF.  
EGF induced activation of Stat5 in hepatocytes 
Stat 5a and Stat 5b are activated by phosphorylation of Tyr-694 and Tyr-699 residues, 
respectively. In cultured hepatocytes we examined the phophorylation of Stat5a and 
Stat5b after stimulation with EGF and TGFα, and compared it with growth hormone 
(GH) and prolactin (PRL) induced phosphorylation. Experiments were performed on 
cultures 3 hours after plating, at a cell density of 20 000 cells per cm2. Whole cell lysates 
were immunprecipitated with antibodies against Stat5b and Stat5a, followed by 
immunoprobing with general anti-phosphotyrosine antibodies (RC-20, PY-20, or 4G10) 
or phosphospecific antibody recognizing Tyr-699. EGF, TGFα, GH and PRL induced 
dose dependent phophorylation of Stat5b measured with general antibodies, and it 
seemed that EGF stimulated a stronger response. But when the immunoblots were probed 
with Tyr-699 antibodies, GH and PRL gave a more pronounced phosphorylation. Stat5a 
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was not measurably phosphorylated on Tyr-694 after stimulation with EGF, but slight 
phosphorylation was detected when probing was performed with general antibodies. 
Similar experiments were done with electromobility-shift-assay (EMSA) using 
the PIE element of the rat β-casein gene as a probe. We analyzed nuclear extracts of the 
hepatocytes for DNA- binding activity of Stat5. Stimulation of hepatocytes with EGF, 
PRL, and GH (at 3 hours of culturing) induced dose-dependent increase DNA binding of 
Stat5b (Stat5a was not detected in these experiments using supershift assays). PRL and 
GH induced stronger and more persistent activation of Stat5b than EGF. Thus, after EGF 
stimulation of the hepatocytes cultured for 3 hours the Stat5b phosphorylation and DNA 
binding activity peaked at 5-15 minutes, before declining and disappering within 60 
minutes. The maximum DNA binding activity of Stat5b was less prominent for EGF than 
PRL and GH, which was in accordance with the phorphorylation of Tyr-699 (see above). 
 The STAT proteins contain a serine residue between residue 720 and 730 in the 
C-terminal region which can be phosphorylated, but the function of these residues are 
uncertain. With an antibody directed towards Ser-730 on Stat5b, we examined 
immunoblots of imunprecipitates from hepatocytes for serine phosphoryltation. The 
results indicated that Stat5b was constitutively phosphorlyated on Ser-730, and that this 
phosphorylation was not affected by treatment with EGF, TGFα, GH or PRL.  
c-Src involvement in EGF induced activation of Stat5b 
We used a specific inhibitor, CGP 77675, to examine c-Src role in EGF receptor 
mediated Stat5b activation in hepatocytes (Missbach et al., 2000; Susa and Teti, 2000). 
CPG77675 was incubated for 90 minutes prior to agonist stimulation of the cells, which 
resulted in a dose depended inhibition of EGF induced tyrosin phosphorylation and PIE 
DNA-binding of Stat5b. This inhibition of Stat5b activation was specific for EGF, as 
CPG77675 did not affect GH or PRL stimulated Stat5b activation. CGP77675 did not 
inhibit EGF induced phosphorylation of EGF receptor and downstream Shc. Erk1/Erk2 
activation was not affected by CGP77675 consentration which completely inhibited 
Stat5b activation. c-Src appeared to be constitutive active in hepatocytes, detected as 
phosphorylation of c-Src substrate paxillin. This constitutive activation was completely 
inhibited with CGP77675 in the same concentration as for Stat5b activation.    
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Downregulation of EGF induced Stat5b activation in mitogenically responsive 
hepatocytes 
Hepatocytes cultured at high density are known to be less responsive to mitogenic stimuli 
than low density cultures (Edwards et al., 2000). In our model system hepatocytes 
cultured at 50 000 cells/cm2 (high density)shows minute responses on EGF induced DNA 
synthesis as compared to cultures of 20 000 cm2 (low density). Also, as described, 
hepatocytes cultured at optimal density seem to get more responsive for EGF induced 
mitogensis in mid/late in G1 phase. This is confirmed by the EGF stimulated DNA 
synthesis measured over a 40 h period, is greater when EGF is added at 24 h than 3 h 
after plating. Furtermore, the EGF induced expression of Cyclin D1 are not affected by 
the timing of addition of EGF, indicating a growth factor dependent restriction point late 
in G1 phase. 
EGF induced Stat5b activation, measured as PIE DNA binding and 
phosphorylation of Tyr-699, was in low density cultures more prominent at 3h than 24h 
after plating, indicating a downregulation. In contrast, in high density cultures the EGF 
induced activation of Stat5b was more conserved at 24 h after seeding. EGF induced EGF 
receptor autophosphorylation, Shc and Erk1/Erk2 phosphorylation were preserved at 24 h 
after plating, as was PRL and GH stimulated Stat5b activation.  
GH and PRL did not stimulate DNA synthesis in hepatocytes themselves, and 
they had no comitgenic effect given as pretreatment (at 3h) on EGF induced DNA 
synthesis. 
Paper II 
The study published in the second paper was done in collaboration with Nilssen L.S. and 
others, and examined the role of EGF receptor transactivation in GPRC agonists 
modulating of EGF stimulated proliferation. Vasopressin, norepheneprine, angiotensin II, 
and prostaglandin F2α were used because they act as comitogens on EGF receptor 
mediated growth in hepatocytes (Dajani et al., 1996; Dajani et al., 1999). In this paper I 
did the immunoprecipitations of EGF receptor activation and downstream signaling 
proteins by GPRC agonists.  
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Pyk2 activation in hepatocytes 
Some GPCR can act as comitogens on EGF induced proliferation in hepatocytes, but by 
them selves have little or no mitogenic effect (Michalopoulos, 1990). The molecular 
mechanisms behind the comitogenic effect are uncertain, and several theories have been 
proposed. One explanation can be that GPCRs may activate intracellular signaling 
cascades which lead to regulation of gene transcription. Pyk2 is non receptor tyrosine 
kinase, like Src, that is reported to be downstream of GPCRs, and could convey such 
signal. 
 Hepatocytes were cultured for 3 h before stimulation with agonists for 5-30 
minutes, followed by harvesting of the cells. Immunoprecitations were done on whole 
cell lysates with antibodies against phosphotyrosine. The immunoprecipitates were 
separated on PAGE gels and blotted to nitrocellulose membranes before immonoprobing 
with anti Pyk antibodies.  
Stimulation with vasopressin, norepheneprine, angiotensin II, and prostaglandin 
2α resulted in phosphorylation of Pyk2, which for vasopressin lasted for at least 30 
minutes. EGF induced no detectable activation of Pyk2.  
GPCR agonists do not transactivate EGF receptor and proximal downstream 
signaling mediators 
GPCR agonists that act as comitogens stimulate ERK activity with peak activity within 3-
5 minutes in hepatocytes (Melien et al., 1998), so transactivation of the EGF receptor 
should happen inside this timeframe. 
 Cultures at 3 h after plating were stimulated with the different GPCR agonists for 
1-60 minutes, with EGF added as a control. The hepatocytes were harvested and whole 
cell lysates were immunoprecipitated with EGF receptor antibodies, before separation 
and immobilizing with western blotting technique. Then the blots were probed with 
phosphotyrosine antibodies before detection. 
  The GPCR agonist studied did not induce pshosphorylation of the EGF receptor 
as an indication of transactiviation, nor did these agonists induce phosphorylation of Shc 
in similar experiments.  
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EGF receptor kinase inhibitor AG1478 does not impair GPCR induced Erk1/Erk2 
activation  
As described, Erk1/Erk2 lie downstream of the EGF receptor, and are important for EGF 
mediated growth. But Erk1/Erk2 are activated upon stimulation with GPRC agonists, 
which could possibly implicated involvement of the EGF receptor. 
 Hepatocytes cultured for 2.5 h before pretreatment with appropriate doses the 
EGF receptor tyrosine kinase inhibitor AG1478 for 30 min, then at 3 h after plating the 
hepatocytes were stimulated with the different GPCR agonists or EGF. Western blotting 
were performed on whole cell lysates, and immunoprobed with phosphor-Erk1/Erk2. 
 We found that AG1478 dose dependently inhibited EGF stimulated Erk1/Erk2 
activity, with complete inhibition at 5µM, but had no effect on GPCR induced activity. 
AG1478 does not inhibit the comitogenic effect of GPCR agonists 
Comitogens exert their effect on proliferation early in the G1 phase in hepatocytes. Later 
in the G1 phase hepatocytes get mitogenically responsive to EGF (Sand and 
Christoffersen, 1987; Thoresen et al., 1990). We used AG1478 to examine the role of 
EGF receptor transactivation on EGF induced DNA synthesis augmented by GPCR 
agonists. 
 Primary cultures of hepatocytes were prepared and cultured as described above. 
GPRC agonists were added to the cultures early in G1 phase, approximately 3-4 hours 
after plating, and EGF was added around 24 h after plating. AG1478 was added early or 
late in the G1 phase depending on the experiment, 3H-thymidine was added as described. 
The hepatocytes were harvested at 50-54 h after plating and lysed, followed by 
precipitation of DNA with acid. Then 3H-thymidine incorporated into DNA was 
measured after filtration.     
 Inhibition of EGF receptor with AG1478 late in the G1 phase completely inhibited 
EGF induced DNA-synthesis. While addition of AG1478 at the time of stimulation with 
GPCR agonists had no or little effect on the additive effect of comitogens on measured 
DNA synthesis.  
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GPRC agonists induce expression of early response genes independently of 
EGF receptor signaling 
GPRC agonists increase the expression of proto-oncogene c-myc, which appear to be 
needed for proliferation in hepatocytes (Gonzalez-Espinosa and Garcia-Sainz, 1992; 
Pelengaris et al., 2002). ATF3 is an other gene that has been shown to have increased 
expression in regenerating liver (Weir et al., 1994). It may be likely that the comitogenic 
effect may be dependent on signaling pathways leading directly from GPCR to gene 
transcription.  
 Similar experiments as described above were performed on the cultures, but 
instead of measuring the DNA synthesis the expression of c-myc and ATF3 were done 
after 1 h ligand stimulation. Gene expression was analyzed bye measuring mRNA 
transcription with nothern blot analysis. 
 Vasopressin, norepheneprine, angiotensin II, and prostaglandin 2α induced 
increased expression of both c-myc and ATF3 in hepatocytes, latter have not been 
demonstrated before. AG1478 had no effect on the expression of these genes.  
 
Discussion 
In this thesis I have included two papers, both where, in collaboration with others in our 
research group, I have examined different aspects of signaling from the EGF receptor. In 
in the first of these I looked at the role of EGF receptor activation and some of the 
proximal downstream signaling mechanisms, and particularly the relationship between 
STAT proteins and mitogenic signaling. 
In the other paper, we studied the regulation of the EGF receptor signaling by 
GPCR, with particularly focus on the question of whether GPCRs exert growth-
promoting effects by transactivating the EGF receptor. 
EGF receptor signaling in mitogenic responsive hepatocytes 
The EGF receptor can be activated by several ligands as described. Upon ligand binding 
receptors dimerize and initiate intracellular signaling by binding and activate intracellular 
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signaling proteins. These proteins are beginnings of the different intracellular signaling 
pathways witch eventually lead to regulation of biological functions. 
 In hepatocytes the EGF receptor can activate different signaling pathways, and the 
role of the different pathways in mitogenic signaling are described earlier. Thus, evidence 
suggests that two signaling pathways are important in EGF receptor induced 
proliferation; namely signalling over MAPK pathway and PI3K (Kong et al., 2000; 
Thoresen et al., 2003). But the roles of other EGF receptor activated pathways in 
mitogenic signaling have been elusive.   
STAT proteins and EGF receptor signaling 
Stat1, Stat3, and Stat5 were first reported to be activated by EGF in liver in mice, and 
studies on hepatocytes and related models suggested that they are involved in regulation 
of specialized differentiated cellular functions (Runge et al., 1998; Wang et al., 1999). In 
hepatocytes Stat3 is associated with acute phase responses, and both Stat3 and Stat5 are 
possibly involved in development and differentiation of hepatocytes. STAT proteins are 
themselves transcription factors, which bind and regulate genes. Among the targets of 
Stat1, Stat3, Stat5a, and Stat5b are the genes for c-Myc, cyclin-D1, c-Fos, and p21waf/cip1, 
which are important in the regulation of proliferation (Quelle et al., 1996; Matsumura et 
al., 1999). This may implicate a role for STAT proteins in growth factor mediated growth 
signaling. 
 In hepatocytes expression of Stat1, Stat3, Stat5a, and Stat5b was detected, and 
Stat1, Stat3, and particularly Stat5b are activated by EGF (Guren et al., 1999). This 
activation is especially apparent in freshly isolated hepatocytes, which are in the G0/early 
G1 phase of the cell cycle. When the hepatocytes come later in G1 phase and get 
mitogenically responsive for EGF, the EGF mediated activation of Stat5b gets less 
pronounced (Guren et al., 2003) Paper 1. 
  In paper 1 we examined the mechanism for EGF-induced activation of Stat5b, 
using primary cultures of rat hepatocytes as a model. EGF-stimulated Stat5b activation 
was detected as phosphorylation with immunoprecipitation technique and blotting with 
phosphotyrosine antibodies, and as DNA binding with EMSA. We compared EGF 
induced Stat5b activation with that of growth hormone (GH) and prolactin (PRL), which 
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are known to activate Stat5b. EGF-induced a stronger, but more transient, 
phosphorylation of Stat5b than GH and PRL when we probed the immunopreciptates 
with a general phosphotyrosine antibody. However, when using an antibody specific for 
Tyr-699, which is the activation site for Stat5b, we detected a lower degree of 
phosphorlyation as compared to GH and PRL.  This was consistent with the DNA 
binding of Stat5b, suggesting that EGF receptor phosphorylates residues on Stat5b not 
involved in activation. The functional role of Stat5b phosphorylation besides Tyr-699 is 
not known, but it may be involved in negative regulation or another unknown function of 
Stat5b utilized by the EGF receptor. 
 Stat5a and Stat5b are known to be phosphorylated on serine residues. This was 
also apparent in hepatocytes. We found that the serine phosphorylation of Stat5b was 
constitutive, and was not influenced by addition of EGF, TGFα, PRL, or GH. It is known 
that Stat5b is serine-phosphorylated on residue Ser-730, and this phosphorylation may be 
important for the modulation of transcription activity (Yamashita et al., 1998). But in 
EGF receptor-mediated activation of Stat5b, the role of serine phosphorylation is still 
unclear. 
  c-Src may be involved in signaling from RTK as described. In various cell models 
it has been reported that Src may activate Stat3 and Stat5 (Bromberg et al., 1998; Abram 
and Courtneidge, 2000; Reddy et al., 2000). Involvement of Src in EGF receptor-
mediated activation of Stat5 has also been described (Olayioye et al., 1999). We used the 
selective Src inhibitor CGP77675 to investigate the role of c-Src in EGF induced 
activation of Stat5b (Susa and Teti, 2000). The results in paper 1 suggest that c-Src is 
required for the EGF receptor mediated activation of Stat5b, since addition of the 
inhibitor blocked the phosphorylation and DNA binding of Stat5b. In contrast, inhibition 
of c-Src did not affect GH- or PRL-induced Stat5b activation. The basal tyrosine kinase 
activity of c-Src was not detectably affected by EGF stimulation, but the basal activity 
was inhibited by CGP77675. This suggests that c-Src is not downstream of the EGF 
receptor, and that co-operation between the EGF receptor and c-Src is needed for Stat5b 
activation. 
 The results in paper 1 also provide more evidence against the involvement of 
Stat5b in EGF induced mitogenesis in hepatocytes. As described, at the time of seeding 
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the hepatocytes are mostly in early G1 phase of the cell cycle, and during culturing they 
get more sensitive to mitogenic stimulation from EGF. In these experiments the EGF 
receptor lost its capability to activate Stat5b completely during time in culture, but the 
receptor retained its ability to activate downstream Shc and MAPK. But PRL and GH 
preserved their capability to activate Stat5b during culturing. These results, taken 
together with data showing that hepatocytes cultured at high density maintained their 
capacity to activate Stat5b after EGF stimulation, suggest that the EGF receptor is 
uncoupled from Stat5b activation mechanisms when the cells become responsive to EGF-
mediated mitogenic stimuli. This may implicate that Stat5b is involved in regulation of 
functions in the cell that are associated with a higher degree of differentiation, which 
corresponds with the role of Stat5b in mammary gland development and lactogenesis 
(Miyoshi et al., 2001). It also produces evidence that the signaling from the EGF receptor 
is modulated depending upon the state of the cell. In cells that are becoming 
mitogenically responsive the EGF receptor is uncoupled from a signaling pathway 
reported to be involved in specialized cellular functions, while retaining and possibly 
enhancing signaling over pathways responsible for conveying the mitogenic signal. 
Regulation of mitogenic EGF receptor signaling by GPCRs 
EGF-induced DNA synthesis can be augmented by addition of ligands that bind GPRC in 
hepatocytes, but the mechanism behind this interaction has been unclear. Recently 
transactivation of the EGF receptor has been suggested as a possible mechanism for 
communication between GPRC and EGF receptor. In paper 2 we show that vasopressin, 
norepheneprine, angiotensin II, and prostaglandin F2α, all which enhance the response to 
EGF, did not induce phosphorylation of the EGF receptor or activation of downstream 
components. And that GPRC induced activation of Erk1/Erk2 is not influenced by 
inhibition of the EGF receptor tyrosine kinase. Also, the inhibition of the EGF receptor 
tyrosine kinase did not prevent the comitogenic effects of GPRC in hepatocytes. Other 
data show that GPRC-induced ERK activity is not needed for the co-mitogenic effect, as 
opposed to EGF-induced mitogenesis were ERK activity is essential (Thoresen et al., 
2003). This suggests that GPRCs use other mechanisms than EGF receptor 
transactivation to enhance the EGF-induced proliferation in hepatocytes.  
 27
 Selective transcription of genes may be a mechanism behind the synergestic effect 
of GPRC-ligands and EGF on cellular proliferation. Several genes are reported to be 
activated in hepatocytes following partial hepatectomy and after stimulation with various 
growth promoting facors (Michalopoulos, 1990). Common for some of the genes are that 
they may be important for the progression of hepatocytes in the cell cycle. One example 
is c-myc, which is a proto-oncogene induced by several growth factors. Another example 
that we have choosed to investigate is ATF3, which has been found to become expressed 
after partial hepatectomy, and is reported to induce DNA synthesis in mouse hepatoma 
cells. We examined the role of these two proteins in hepatocytes stimulated with EGF, 
vasopressin, norepheneprine, angiotensin II, and prostaglandin F2α. All GPRC agonists 
induced expression of c-myc mRNA and ATF3 mRNA, providing a possible mechanism 
for the growth-promoting effect of these ligands. This effect was independent of EGF 
receptor transactivation. We also showed that Pyk2 was activated upon stimulation with 
vasopressin, norepheneprine, angiotensin II, and prostaglandin F2α, and may be a part of 
the downstream signaling pathway from the GPCRs. 
Conclusions 
1. We found that Stat5b is activated in hepatocytes by EGF detected as tyrosine 
phosphorylation and DNA binding by a Src dependent mechanism, in contrast to 
prolactin and growth-hormone induced Stat5b activation. In addition, this 
activation was downregulated in mitogenically responsive hepatocytes, thus 
providing evidence that Stat5b is not required for mitogenic signaling from the 
EGF receptor. 
 
2. The GPCR ligands vasopressin, norepheneprine, angiotensin II, and prostaglandin 
F2α, which acts as co-mitogens on EGF-induced proliferation in hepatocytes, do 
not exert their effect by transactivation of the EGF receptor. But rather by 
regulation of gene expression, as these agonists induce transcription of early 
response genes c-Myc and ATF3.  
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EGF Receptor-Mediated, c-Src-Dependent, Activation
of Stat5b is Downregulated in Mitogenically
Responsive Hepatocytes
TORMOD K. GUREN,1* JOHN ØDEGA˚RD,1 HILDE ABRAHAMSEN,2 G. HEGE THORESEN,1
MIRA SUSA,3 YVONNE ANDERSSON,4 EVA ØSTBY,1 AND THORALF CHRISTOFFERSEN1
1Department of Pharmacology, Faculty of Medicine, University of Oslo,
Oslo, Norway
2Department of Medical Biochemistry, Faculty of Medicine,
University of Oslo, Oslo, Norway
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Signal transducer and activator of transcription (STAT) proteinsmay be activated by
epidermal growth factor (EGF), but their role in EGF receptor-mediated mitogenic
signaling is not clear.We previously showed that Stat5bwas activated by EGF in rat
hepatocytes in primary monolayer culture. In the present study, we found that EGF
induced tyrosine phosphorylation of Stat5b both on Tyr-699,which correlatedwith
specific DNA binding activity, and also on other tyrosine residues. The Src tyrosine
kinase inhibitor CGP77675 blocked the EGF-induced activation of Stat5b, but did
not affect the Stat5b activation by growth hormone (GH) or prolactin (PRL). The
Stat5b response to EGFwasmost pronounced soon (3 h) after plating (early G1) and
at high cell density (50,000 hepatocytes per cm2). However, at this cell density EGF
did not stimulate DNA synthesis. In hepatocytes at 24 h of culturing (mid/late G1)
with 20,000 cells per cm2, EGF induced strong phosphorylation of the EGF
receptor, aswell as Shc andERK, and stimulatedDNAsynthesis, but did not activate
Stat5b, although the Stat5b response to GH or PRL was retained. A strong GH-
induced Stat5b activation neither influenced the DNA synthesis alone nor
enhanced the mitogenic effect of EGF. The results show that EGF induces tyrosine
phosphorylation andDNA-binding activity of Stat5b in amanner different fromGH
and PRL, apparently by a Src-dependent mechanism. The data also provide further
evidence that Stat5b is not required for mitogenic signaling from the EGF
receptor. J. Cell. Physiol. 196: 113–123, 2003.  2003 Wiley-Liss, Inc.
The epidermal growth factor (EGF) receptor mediates
regulation of cell proliferation and other cellular func-
tions through a complex set of mechanisms that are still
not fully understood. Ligand binding elicits receptor
dimerization, intrinsic tyrosine kinase activation, and
autophosphorylation, resulting in recruitment and
activation of various signal molecules (Schlessinger,
2000). A number of proteins that interact with the EGF
receptor and may serve as signal mediators have been
identified (van der Geer et al., 1994), and some of the
downstream signaling pathways have also been deli-
neated, including the Ras-mediated cascade that acti-
vates the ERK type of MAP kinases (Chang and Karin,
2001).
Members of the family of ‘signal transducer and
activator of transcription’ (STAT) proteins (Darnell,
1997), first discovered as mediators in the action of
interferons and other cytokines (Ihle, 2001), have also
been implicated in the mechanisms of signaling from
growth factor receptors, including the EGF receptor
(Leaman et al., 1996). The STAT proteins are a group of
latent, receptor-activated transcription factors, which,
upon phosphorylation on a single tyrosine residue,
dimerize and translocate to the nucleus, where they
 2003 WILEY-LISS, INC.
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signal transducer and activator of transcription; GH, growth
hormone; PRL, prolactin; EMSA, electrophoretic mobility-shift
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bind to specific sequences in the promoter of target
genes (Darnell, 1997). They participate in diverse gene
regulation involved in cell differentiation, survival, and
proliferation, and possibly also in oncogenesis (Darnell,
1997; Bowman et al., 2000). Seven STAT genes have
been identified in mammalian cells, the most widely
expressed being Stat1, Stat3, and the highly homolo-
gous Stat5a and Stat5b. There is increasing evidence
that the different STATs serve distinct functions in the
cells (Bromberg and Darnell, 2000). Thus, Stat1 seems
to primarily exert antiproliferative effects (Chin et al.,
1996; Bromberg et al., 1998a). In contrast, Stat3 may
have promitogenic and antiapoptotic effects and has
been implicated in malignant transformation in some
cells (Bromberg et al., 1999; Song and Rubin Grandis,
2000). Stat5a and Stat5b in hematopoietic cells seem to
promote growth, inhibit apoptosis, and may be involved
in malignant transformation (Matsumura et al., 1999;
Nosaka et al., 1999; Demoulin et al., 2000), and are also
essential mediators of the effects of prolactin (PRL) and
growth hormone (GH) as well as IL-2 and other
cytokines (Groner and Gouilleux, 1995; Grimley et al.,
1999; Moriggl et al., 1999; Herrington et al., 2000; Lin
and Leonard, 2000). However, although STAT proteins
in some cells have been found to be phosphorylated
and activated in response to growth factors, including
EGF (Ruff-Jamison et al., 1993, 1994, 1995; Richer
et al., 1998; Guren et al., 1999; Luetteke et al., 1999;
Olayioye et al., 1999), PDGF (Valgeirsdottir et al., 1998;
Sachsenmaier et al., 1999), and VEGF (Bartoli et al.,
2000), their exact function in receptor tyrosine kinase
signaling has not been defined, and the role of STAT
proteins in EGF receptor-mediated mitogenic mechan-
isms is not known.
Hepatocytes in primary monolayer culture is an
epithelial model where several mechanisms of hormonal
growth regulation, including growth-promoting effects
of EGF, have been studied (for review, see Christoffer-
sen et al., 2000). The purpose of the present study was to
examine the EGF receptor-mediated activation of Stat5
and its relationship to the mitogenic effect of EGF, using
cultured rat hepatocytes as a model. It has been shown
that Stat1, Stat3, and Stat5 in mouse liver are activated
in vivo upon EGF treatment (Ruff-Jamison et al., 1993),
and we found that in cultured rat hepatocytes Stat3 is
constitutively active, while only Stat5b is activated by
EGF (Guren et al., 1999). In the present study, we have
further examined the mechanisms of EGF receptor-
mediated activation of Stat5b and its relationship to the
mitogenic effect of EGF in cultured hepatocytes. The
results show that EGF induces tyrosine phosphoryla-
tion and DNA-binding activity of Stat5b in a manner
different from GH and PRL, apparently by a Src-
dependent mechanism. They also suggest that the
activation of Stat5b, in contrast to the EGF-induced
stimulation of ERK, is not part of the mitogenic signal
from the EGF receptor.
MATERIALS AND METHODS
Materials
EGF (mouse, receptor grade) and ovine PRL were
obtained from Sigma (St. Louis, MO). Recombinant
human GH was a gift from Pharmacia & Norge AS (Oslo,
Norway). The Src inhibitor CGP77675, described in
Missbach et al. (1999); Susa et al. (2000) was a gift from
Novartis Pharma AG (Basel, Switzerland). Polyclonal
rabbit antibodies against Stat5b (C-17, sc-835) and
Stat5a (L-20, sc-1081), and EGF receptor (sc-03) were
from Santa Cruz Biotechnology (Santa Cruz, CA).
Polyclonal rabbit antisera specific to peptides corre-
sponding to the unique C-termini of Stat5a or Stat5b
(Kirken et al., 1997), and antiserum recognizing Stat5a
and Stat5b phosphorylated on Ser-725 and Ser-730,
respectively (Yamashita et al., 1998), were kindly
provided by Dr. Hallgeir Rui, Department of Pathology
USUHS, Bethesda, MD. Polyclonal rabbit antibodies
against Shc (Cat. No. 06-203) and Stat5a/Stat5b phos-
phorylated on Tyr-694/Tyr-699 (Cat. No. 05-495) were
from Upstate Biotechnology (Lake Placid, NY). Anti-
bodies against phospho-p44/42 MAPK (p-Thr-202/p-
Tyr-204) and Cyclin D1 were from Cell Signalling
Technology (Beverly, MA). Antibodies against paxillin
were from BD Transduction Laboratories (Lexington,
KY). The source of other materials has been described
(Guren et al., 1996, 1999; Thoresen et al., 1998).
Isolation and culture of hepatocytes
and cell lines
Hepatocytes were isolated from male Wistar rats as
previously described (Seglen, 1976; Christoffersen et al.,
1984). The cells were seeded onto Costar plastic flasks at
a density of 20,000 or 50,000 cells per cm2 and cultured
in a serum-free 1:1 combination of Williams’ E medium
and Dulbecco’s modified Eagle’s (DMEM) medium with
collagen (3 mg/ml), 100 nM insulin, and 25 nM dexa-
methasone (Thoresen et al., 1998).
Oligonucleotide probes
Single stranded oligonucleotides were synthesized at
the Biotechnology Centre of Oslo, University of Oslo,
Norway. The following sequence was used: 50-GGA CTT
CTT GGA ATT AAG GGA-30, containing the PRL-
inducible element (PIE) of the rat b-casein gene, which
binds Stat5 and Stat1 (Wakao et al., 1994). The
oligonucleotides were end-labeled using [g-32P]ATP
(Amersham Biosciences, Buckinghamshire, UK) and a
T4 polynucleotide kinase (New England Biolabs, Bev-
erly, MA), followed by annealing to the complementary
sequence to obtain double-stranded probes, and purified
as described in Guren et al. (1999). The specific activity
of the probes was approximately 5–6,000 cpm/fmol.
Preparation of nuclear extracts and electrophoretic
mobility-shift assay (EMSA)
Nuclear extracts were prepared as previously de-
scribed (Guren et al., 1999). In brief, hepatocytes in
primary culture were incubated with agonists as in-
dicated in the figure legends, rapidly washed, and kept
on ice for lysis in 1 ml hypotonic buffer A, containing
20 mM HEPES, pH 7.9, 10 mM KCl, 10% glycerol, 1 mM
EDTA, 1 mM EGTA, 20 mM NaF, 1 mM Na4P2O7,
0.1 mM Na3VO4, 50 mM Na2MnO4, 1 mM DTT, and
Complete Protease Inhibitor (1 tablet per 50 ml solution)
for 15 min. Monolayers were scraped with a rubber
policeman and collected. Nonidet P-40 was added to
lysates to a final concentration of 0.20%, followed
by wortexing for 15 sec. The nuclei were pelleted by
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centrifugation at 10,000g for 30 sec, and the nuclear
pellet was resuspended in 100 ml of a high salt extraction
buffer C (buffer A with addition of 420 mM NaCl), under
gentle rocking for 30 min.
EMSAs were performed as described (Guren et al.,
1999). In brief, portions (10 mg) of nuclear extracts were
preincubated for 15 min in a binding buffer containing
13 mM HEPES, pH 7.9, 80 mM NaCl, 8% glycerol,
0.15 mM EDTA, and 1 mM dithiotreitol, in presence of
3 mg double stranded poly(dI-dC) (Amersham Bio-
sciences, Buckinghamshire, UK). One microlitre of
32P-labelled probe was added to a total volume of 20 ml,
and the incubation was continued for 30 min. In super-
shift analysis of PIE-binding proteins, the experiments
were performed by including high-titered polyclonal
antibodies against Stat5a or Stat5b (Kirken et al., 1997)
or polyclonal Transcruz antibodies against the C ter-
minus of Stat1 (Santa Cruz Biotechnology) for further
30 min, before addition of labeled probes. Ten micro-
litres of the incubated DNA–protein complexes were
loaded on 5% non-denaturated polyacrylamid gels in
0.5 TBE (89 mM Tris-HCl, 89 mM borate, 2 mM
EDTA) and electrophorezed at 210 V. The gels were
dried and the retarded complexes visualized by auto-
radiography.
Cell lysis and immunoprecipitaion
The method is based on previously described methods
(Yamashita et al., 1998). After agonist stimulation, the
plated cells were rapidly rinsed twice in ice cold 0.9%
NaCl, and once in immunoprecipitation (IP) buffer A
(50 mM Tris-HCl, pH 7.4, 280 mM NaCl, 0.2 mM EDTA,
2.0 mM EGTA, 10% glycerol, 1 mM activated Na3VO4,
50 mM NaF, 30 mM Na4P2O7, 1 mM phenylmethylsul-
fonyl fluoride (PMSF), and Complete protease inhibitor
(Roche Diagnostics, Basel, Switzerland, Germany).
Cells were lysed in 1 ml IP buffer A supplied with
Nonidet P-40 (final concentration 1%) for 15 min on ice
and the lysates were transferred into Eppendorf tubes.
Insoluble material was pelleted at 13,000g for 10 min at
48C. Depending on the experiment, clarified lysates
(approximately 250 mg protein) were incubated for
120 min with 1 mg polyclonal rabbit antibodies and the
complexes were captured overnight with Dynabeads
(Dynal AS, Oslo, Norway) 0.25 mg per extract, coated
with sheep anti-goat antibodies (a gift from Dr. Kjell
Nustad, The Norwegian Radium Hospital, Oslo, Nor-
way). Complexes were washed three times with IP
buffer A with 0.5% Nonidet P-40.
Shc proteins were immunoprecipitated under dena-
turating conditions. After agonist stimulation for the
time indicated, the cells were lysed in 250 ml boiling lysis
buffer (10mMTris-HCl, pH7.4,2% SDS,1mMNa3VO4),
and the lysates were boiled for 5 min. After 10 passages
through a 20 G gauge on ice, the lysates were cleared
by centrifugation (19 min, 13,000g at 48C). Two hundred
and fifty micrograms of lysate was incubated for 2 h in IP
buffer B (10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 0.5%
NP-40, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA,
0.2 mM PMSF, 0.2 mM Na3VO4) with the phosphoty-
rosine antibody PY-99 (Santa Cruz Biotechnology). The
immune complexes were captured with Dynabeads,
coated with sheep anti-mouse antibodies overnight at
48C, and washed twice with ice-cold IP buffer B. The
proteins were released from the Dynabeads by boiling
for 5 min in 2 Laemmli sample buffer.
Immunoblots
Immunoprecipitates or aliquots of 20 mg cell protein
(total cell lysate prepared in Laemmli buffer) were
separated in 8–12%, depending on the protein weight
(w/v) polyacrylamide (30:1 acrylamide: N0N0-bis-acryla-
mide) gel electrophoresis (PAGE), and transferred to
nitro-cellulose membranes. The filters were blocked in
T-TBS (10 mM Tris-HCl, pH 8.0, 150 mM NaCl) with 5%
(w/v) low fat dry-milk and 0.05% Tween-20), followed
by incubation overnight at 48C with primary anti-
bodies. The secondary antibody, horseradish peroxi-
dase-conjugated sheep anti-rabbit IgG, was incubated in
blocking solution for 1.5 h. The blots were visualiz-
ed with Enzyme-linked Chemiluminescence Reagent
(ECL, Amersham Pharmacia Biotech). Densitometric
analysis of the bands was obtained with the Labworks
software package (UVP, Cambridge, UK). For detection
of phosphotyrosine, the membranes were blocked in
TTBS containing 1% BSA and incubated overnight at
48C with the anti-phosphotyrosine antibodies RC20
or PY-20 (Transduction Laboratories). When using
the 4G10 anti-phosphotyrosine antibody (Upstate Bio-
technonlogy, Lake Placid, NY), a protocol recommended
by the manufacturer was followed. After detection of
tyrosine phosphorylation, the membranes were washed
in H2O, stripped in 0.5 M NaOH, and blocked before
reprobing with another antibody.
Other methods
DNA synthesis was measured by thymidine incor-
poration (Refsnes et al., 1994). [6-3H]-Thymidine (3H-
TdR) was added to the cultures (1 mCi/ml, 0.125 Ci/
mmol) at 24 and 48 h after plating. Protein contents of
nuclear extracts and whole-cell lysates were determin-
ed using the Comassie Plus Protein Assay (Pierce,
Rockford, IL).
RESULTS
Effect of EGF, TGFa, PRL, and GH on tyrosine
phosphorylation of Stat5 in cultured hepatocytes
Phosphorylation of the Tyr-694 and Tyr-699 residues
of Stat5a and Stat5b, respectively, leads to activation of
the Stat5 proteins (Grimley et al., 1999). We first
examined EGF receptor-mediated tyrosine phosphory-
lation of Stat5a and Stat5b in the hepatocytes, compar-
ing the effects with the responses to PRL and GH. These
experiments were performed at 3 h after plating, using a
cell density of 20,000 hepatocytes per cm2.
EGF and TGFa, like PRL and GH, induced tyrosine
phosphorylation of Stat5b in the cultured hepatocytes
(Fig. 1). After IP from whole-cell lysates, immunoblot
probing with general anti-phosphotyrosine antibodies
(RC-20, PY-20, or 4G10) showed dose-dependent ago-
nist-induced tyrosine phosphorylation of Stat5b (Fig. 1A
and data not shown). The EGF-induced phosphorylation
of Stat5b was rapid and transient (see below). Using
these general anti-phosphotyrosine antibodies for detec-
tion, it was consistently found that EGF produced a
larger maximal phosphorylation of Stat5b than did PRL
or GH (Fig. 1A,C). However, when the Stat5b immuno-
precipitates were blotted with an antibody recognizing
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Stat5b phosphorylated on Tyr-699, the EGF-induced
phosphorylation generally was of less magnitude than
the effects of PRL or GH (Fig. 1B,C). Stat5a, which is also
expressed in the primary cultures of rat hepatocytes
(Guren et al., 1999), was not measurably phosporylated
on Tyr-694 in response to EGF, while a slight phosphor-
ylation was detected by a general phosphotyrosine
antibody (Fig. 1D). This may be consistent with the
observation that EGF appeared to induce phosphory-
lation of other tyrosine sites than Tyr-694 in Stat5a
(Olayioye et al., 1999). After treatment with PRL or GH
a small amount of Stat5a phosphorylated on Tyr-694
was noted (Fig. 1E).
Constitutive serine phosphorylation of Stat5b
The C-terminal region of most STAT proteins contains
a serine residue between position 720 and 730, and it
has been suggested that phosphorylation of this serine
may modulate the transcriptional ability of certain
STAT proteins (Decker and Kovarik, 2000). Ser-730 on
Stat5b can be phosphorylated (Grimley et al., 1999). The
functional importance of this is not clear but there is
evidence that phosphorylation of Ser-730 modulates the
effects on gene transcription of Stat5b (Park et al., 2001).
We examined serine phosphorylation of Stat5b in the
hepatocytes, using a specific antibody directed towards
Ser-730 (Yamashita et al., 1998). The results indicated
that Ser-730 in Stat5b was constitutively phosphory-
lated in the hepatocytes. However this phosphorylation
was not altered significantly upon treatment with EGF,
TGFa, PRL, or GH (Fig. 1F).
Agonist-induced DNA-binding activity of Stat5b:
differential responses to EGF, PRL, and GH
Nuclear extracts of the hepatocytes were analyzed
(EMSA) for agonist-induced activation of Stat5, in terms
of binding to the PIE of the rat b-casein gene (Wakao
et al., 1994). Stimulation of cells (at 3 h of culturing) with
EGF, PRL, or GH for 15 min prior to harvesting induced
dose-dependent increases in the amount of Stat5 bound
to the PIE probe (Fig. 2A). Supershift assays, using
antisera that discriminate between Stat5a and Stat5b,
raised against their C-terminal parts (Kirken et al.,
1997), showed that the EGF-induced PIE-binding
complexes consisted of only Stat5b. Thus, these results
together with the tyrosine phosphorylation data (Fig. 1)
corroborate our previous suggestion (Guren et al., 1999)
that EGF selectively activates Stat5b in hepatocytes
Fig. 1. Phosphorylation of Stat5a and Stat5b by EGF, TGFa, PRL, or
GH in cultured hepatocytes. Hepatocytes plated and cultured for 3 h
at 20,000 cells/cm2, were stimulated for 15 min with agonist. Stat5a or
Stat5b was immunoprecipitated from whole-cell lysates using poly-
clonal antibodies, separated by SDS–PAGE (10%), and transferred to
nitrocellulose membranes. A: Tyrosine phosphorylation (pY) was
detected by the general anti-phosphotyrosine antibody RC20 directly
conjugated to horseradish peroxidase. The membranes were stripped
and reprobed with a specific Stat5b antibody (discriminating between
Stat5a and Stat5b, Kirken et al., 1997). B: The membranes were
probed with an antibody recognizing Stat5b phosphorylated on Tyr-
699 (pY699), and were stripped and reprobed with a specific Stat5b
antibody. C: Densitometric analysis of agonist-induced Stat5b
tyrosine phosphorylation (pY, left) and Tyr-699 phoshorylation
(pY699, right). The hepatocytes were stimulated with EGF (100 nM),
PRL (1 mM), or GH (100 nM) and phosphorylation was detected by IP
and Western blots as described in A and B. The data (OD ratio; i.e.,
band density normalized to total Stat5b in arbitrary units) are
meanSEM of values from three independent experiments. D: The
membranes were probed with an antibody recognizing Stat5a phos-
phorylated on Tyr-694 (pY694) and were stripped and first reprobed
with a specific a general phosphotyrosine antibody (RC-20) and strip-
ped again before Stat5a was detected with a specific Stat5a antibody.
E: The membranes were probed with an antibody recognizing Stat5a
phosphorylated on Tyr-694 (pY694) and were stripped and reprobed
with a specific Stat5a antibody (Kirken et al., 1997). F: Upon IP with
specific Stat5b antibodies (Kirken et al., 1997), serine phosphorylation
was detected with a polyclonal antibody recognizing Stat5b phos-
phorylated on Ser-730 (pS730) (Yamashita et al., 1998). The mem-
branes were stripped and reprobed with a specific Stat5b antibody.
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(Fig. 2B). PRL and GH also activated predominantly
Stat5b in the cells. Although we observed a weak
phosphorylation of Stat5a on Tyr-694 after PRL or GH
stimulation (Fig. 1E) no significant supershift of the
Stat5 complexes was detected with a Stat5a antibody
(Fig. 2B).
The activation of Stat5b induced by EGF differed
from the effects of PRL and GH in being more rapid and
transient. Thus, after EGF stimulation both the tyro-
sine phosphorylation of Stat5b (data not shown) and the
PIE-binding activity in nuclear extracts were maximal
at 5–15 min and then declined, disappearing within
60 min, while PRL and GH produced more sustained
effects (Fig. 2C and data not shown). Quantification of
the radioactivity of the retarded Stat5b–PIE complexes
in the EMSA gels showed that this effect of EGF was
half-maximal at about 10 nM (Fig. 2D). The maximal
effect of EGF was significantly lower than the responses
to PRL and GH (Fig. 2D), which is in accordance with the
difference in phosphorylation of Stat5b at Tyr-699
shown in Figure 1B,C.
c-Src tyrosine kinase inhibitor CGP77675
selectively blocks EGF-induced
activation of Stat5b
Src tyrosine kinase seems to be involved in signaling
from certain receptor tyrosine kinases and cytokine
receptors and may activate Stat3 in some cell models
(Bromberg et al., 1998b; Turkson et al., 1998; Biscardi
et al., 1999; Abram and Courtneidge, 2000). Src has also
been reported to activate Stat5 (Kazansky et al., 1999;
Reddy et al., 2000), and recent findings in A431 and
HepG2 cells suggest that c-Src may be involved in EGF
receptor-mediated activation of Stat5 (Olayioye et al.,
1999; Wang et al., 1999), while PDGF-induced Stat5
activation was independent of c-Src and c-Fyn in some
transfected cells and cell-free systems (Paukku et al.,
2000). To examine the role of c-Src in the effect of EGF on
Stat5b activation in the cultured hepatocytes, we
preincubated the cells for 90 min with CGP77675, an
inhibitor of the c-Src kinase (Missbach et al., 1999; Susa
et al., 2000), prior to stimulation with an agonist.
CGP77675 dose dependently inhibited EGF-induced
tyrosine phosphorylation and PIE-binding activity of
Stat5b (Fig. 3A and data not shown), with IC50 at about
0.5–1 mM (Fig. 3C), which is in the same range as found
for inhibition of tyrosine phosphorylation of Fak and
paxillin in Src-overexpressing cells (Missbach et al.,
1999).
The inhibition of Stat5 activation by CGP77675 was
specific for EGF, as it did not detectably affect tyrosine
phosphorylation or the rise in PIE-binding activity
induced by PRL or GH (Fig. 3B). Furthermore, the
Fig. 2. Differential effects of EGF, PRL, and GH on DNA-binding
activity of Stat5b in cultured hepatocytes. Hepatocytes cultured for 3 h
at 20,000 cells/cm2, were stimulated with EGF, PRL, or GH for 15 min
or the time indicated before harvesting. Ten micrograms of nuclear
extracts were subjected to EMSA, using a 32P-end labeled oligonucleo-
tide probe from the prolactin-inducible element (PIE) from the rat b-
casein gene promoter as a probe (Wakao et al., 1994). A: Dose-
dependency of Stat5b PIE-binding activity induced by EGF, PRL, and
GH. B: Supershift analysis. The nuclear extracts were incubated with
polyclonal antibodies raised against Stat1, Stat5a, or Stat5b (Kirken
et al., 1997) 30 min before the probe was added. The free probe is not
shown. C: Time courses. Hepatocytes were stimulated with EGF
(100 nM), PRL (1 mM), or GH (100 nM). Nuclear extracts were
subjected to EMSA. The free probe is not shown. D: Retarded bands
from EMSA were cut out of the dried gels. The radioactivity of the
bands was quantified in a scintillation counter (graph).
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CGP77675 did not inhibit EGF-induced tyrosine auto-
phosphorylation of the EGF receptor (Fig. 3D). Neither
did preincubation with CGP77675 at 1–2.5 mM, i.e.,
concentrations that completely inhibited EGF-induced
tyrosine phosphorylation and PIE-binding activity of
Stat5b, affect the EGF-induced phosphorylation of ERK,
which required 10 mM of CGP77675 for significant
inhibition (Fig. 3E).
EGF-induced Stat5b activation
is downregulated in mitogenically
responsive cultured hepatocytes
Previous studies have shown that hepatocytes cul-
tured at high cell densities are less responsive to mito-
genic stimulation than low-density cultures (Nakamura
et al., 1983; Edwards and Michalopoulos, 2000). This is
also shown in Figure 4A, which compares the DNA
synthesis in hepatocytes at 20,000 and 50,000 cells per
cm2. Furthermore, the hepatocytes (when cultured at an
optimal density) become more responsive and sensitive
to mitogenic stimulation by EGF when they have
traversed the first part of the G1-phase (Sand and
Christoffersen, 1987; Wollenberg et al., 1989; Loyer
et al., 1996), apparently reflecting a requirement for the
mitogen at a restriction point in mid/late G1 (Loyer et al.,
1996). Consistent with this, Figure 4B,C shows that in
different EGF-treated cultures cyclin D1 is expressed at
42 h after plating, irrespective of whether EGF is added
at 3 or 24 h, and that the DNA synthesis (measured as
3H-TdR incorporation during a 40 h period) is markedly
larger with addition of EGF at 24 h as compared to 3 h.
Thus, low-density cultures (20,000 cells per cm2) at a
late point (24 h) of culturing represent hepatocytes
that are responsive to the mitogenic effect of EGF in
contrast to high density and/or early cultures.
Figure 4 shows that when the hepatocytes were
cultured at a density of 50,000 cells per cm2, EGF did
not significantly stimulate DNA synthesis; however, in
these cultures Stat5b was clearly phosphorylated on
Tyr-699 and activated by EGF, and, in particular, the
ability of the cells to produce a Stat5b response to EGF
was retained for at least 24 h in these high-density
cultures. In contrast, in cultures with 20,000 cells per
cm2, exposure to EGF at 24 h after seeding efficiently
stimulated the DNA synthesis (Fig. 4A,C) but did not
elicit any measurable effect on Stat5b, in terms of
phosphorylation at Tyr-699 or DNA-binding activity
(Figs. 4D,E and 5A,B), although tyrosine phosphoryla-
tion of Stat5b was detected with a general phospho-
tyrosine antibody, suggesting phosphorylation on other
tyrosine residues than Tyr-699 upon EGF stimulation
(Fig. 5B). Thus, when the hepatocytes were in a state
where they were highly responsive to the mitogenic
stimulus, i.e., in low-density cultures at 24 h after
plating, the effect of EGF on Stat5b was downregulated.
This downregulation of mechanisms activating Stat5b
was selective for EGF, since PRL and GH markedly
phosphorylated and activated Stat5b under the same
conditions (Fig. 5A,C and data not shown). Further-
more, EGF did not influence the GH-induced activation
of Stat5b (Fig. 5C).
At 24 h in low-density cultures, EGF induced a rapid
autophosphorylation of the EGF receptor (Fig. 5D), and,
in contrast to the lack of Stat5b activation, several other
EGF receptor-mediated signaling mechanisms were
sustained in the mitogenically responsive hepatocytes.
Fig. 3. Selective inhibition of EGF-induced activation of Stat5b by
the Src tyrosine kinase inhibitor CGP77675. Hepatocytes cultured for
3 h at 20,000 cells/cm2 were stimulated with agonists after 90 min
pretreatment of the Src tyrosine kinase inhibitor CGP77675 or DMSO
(solvent, in control cells). A, B: Nuclear extracts obtained after
stimulation with EGF (10 nM), PRL (1 mM), or GH (100 nM) for 15 min
were subjected to EMSA, using a 32P-end labeled PIE as probe. The
free probe is not shown. Pretreatment with DMSO had no effect on the
EGF-induced Stat5b responses; neither did CGP77675 alone affect
Stat5b (data not shown). C: The retarded complexes bands of A were
cut out of the dried gel and the radioactivity was counted (graph).
D: EGF receptor was immunoprecipitated from whole-cell lysates
from hepatocytes stimulated with EGF (10 nM) by polyclonal
antibodies against the EGF receptor, separated in SDS–PAGE (8%),
and transferred to nitrocellulose membranes. Tyrosine phosphoryla-
tion (pY) was detected by the phosphotyrosine antibody 4G10. The
membranes were stripped and reprobed with an EGF receptor
antibody. E: Whole-cell lysates from hepatocytes stimulated with
EGF (10 nM) for 5 min were separated by SDS–PAGE (12%),
transferred to nitrocellulose membranes. ERK phosphorylation was
detected by a specific antibody against double phosphorylated (active)
ERK.
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Thus, we found a marked EGF-induced phosphorylation
of p52/Shc and p46/Shc (Fig. 5E). Furthermore, treat-
ment with EGF caused a rapid phosphorylation of ERK
in the mitogenically responsive hepatocytes (Fig. 5F),
and, in agreement with our previous observation (Guren
et al., 1999), elicited a strong increase in ERK activity. It
should be noted that the magnitude of the Shc or ERK
responses did not decrease from 3 to 24 h (Fig. 5). Other
experiments have shown that inhibition of a sustained
EGF-induced ERK activation blocks the DNA synthesis
(Thoresen et al., 2003).
GH (Fig. 6) and PRL (data not shown) did not
stimulate DNA synthesis, and pre-treatment with GH
(at 3 h) did not enhance the mitogenic effect of EGF
(added at 24 h, Fig. 6). This provides further evidence
that activation of Sta5b is not required for stimulation of
DNA synthesis in hepatocytes.
DISCUSSION
The role of STAT proteins in the signaling from
growth factor receptors is not clarified. Although EGF
receptor-mediated activation of Stat5 has been ob-
served, its function in epithelial cells is not well under-
stood. The present study, using rat hepatocytes in
primary monolayers as the cell model, provides further
evidence that EGF can stimulate tyrosine phosphoryla-
tion and induce specific DNA-binding activity of Stat5b.
Our results show that the pattern of phosphorylation
and activation of Stat5b induced by EGF in hepatocytes
differs qualitatively from the effects of GH and PRL and
apparently was Src-dependent. Furthermore, the study
also provides evidence against a requirement for EGF-
induced Stat5b activation in mitogenic signaling from
the EGF receptor in these cells.
When immunoprecipitates were probed with a gen-
eral phosphotyrosine antibody, EGF was found to cause
a tyrosine phosphorylation of Stat5b that was more
pronounced than the effects of PRL and GH, but was
transient. In contrast, specific Tyr-699 phosphorylation
and DNA-binding activity of Stat5b elicited by maxi-
mally effective concentrations of EGF were of lower
magnitude than the responses to PRL or GH. Also,
under conditions where the EGF-induced activation of
Stat5b was downregulated, tyrosine phosphorylation of
Stat5b could nevertheless be detected with a general
phosphotyrosine antibody. Taken together, these re-
sults suggest that EGF, but apparently not PRL or GH,
may induce phosphorylation of tyrosine residues other
than Tyr-699 in Stat5b. Recently the Tyr-725, -740, and
-743 of Stat5b were identified as residues that are
phosphorylated in response to EGF in transfected
GHR293 cells (Kloth et al., 2002). The functional role
of the phosphorylation of the additional Stat5 tyrosine
residue(s) is not known, but could be involved in
negative regulation of transcription (Kloth et al., 2002)
or reflect a function of Stat5 utilized by the EGF receptor
but not related to DNA binding activity.
Fig. 4. EGF-induced activation of Stat5b and DNA synthesis at dif-
ferent culturing conditions. Hepatocytes cultured at low (20,000 cells/
cm2) or high (50,000 cells/cm2) density for various time periods.
A: Hepatocytes precultured for 24 h were stimulated with EGF. 3H-
thymidine incorporated into DNA was assessed in the following 48 h.
Data are the meanSEM of triplicates cultures in a typical
experiment. B: Expression of Cyclin D1 induced by (10 nM) addition
of EGF at 3 or 24 h after plating. The cells were harvested at the time
indicated, whole-cell lysates were analyzed by immunoblotting with
an antibody against Cyclin D1. C: DNA synthesis induced by EGF
(10 nM) addition at 3 or 24 h after plating, assessed as 3H-thymidin
incorporation in the period 3–43 h or 24–64 h, respectively (mean
SEM of triplicate cultures from a representative experiment). D:
Hepatocytes cultured for 3 or 24 h were stimulated with EGF (100 nM)
for 15 min and harvested. Lysates were immunoprecipitated with
Stat5b antibodies (Kirken et al., 1997) and tyrosine phosphorylation
was detected in Western blots by an antibody recognizing Stat5b
phosphorylated on Tyr-699 (pY699). The membranes were stripped
and reprobed with a specific Stat5b antibody. E: Hepatocytes cultur-
ed for 3, 9, or 24 h were stimulated with EGF (100 nM) for 15 min and
harvested. Nuclear extracts were subjected to EMSA, using a 32P-end
labeled PIE as probe. The free probe is not shown.
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There are data suggesting that STAT proteins may
have a role in cellular actions of Src (Bromberg et al.,
1998b; Turkson et al., 1998; Garcia et al., 2001). The
present results with the inhibitor CGP77675, suggested
that c-Scr tyrosine kinase is selectively involved in the
EGF-induced activation of Stat5b in hepatocytes. These
findings obtained in normal cells are in agreement with
results indicating a role of c-Src tyrosine kinase in the
EGF receptor-mediated activation of Stat5 in A431 and
HepG2 cells (Olayioye et al., 1999; Wang et al., 1999). We
have observed that EGF induces tyrosine phosphoryla-
tion of paxillin, which may be a downstream response to
c-Src (Missbach et al., 1999), and was sensitive to
pharmacological inhibition of c-Src, and this effect was
more pronounced in high-density cultures (data not
shown). We also observed a basal tyrosine kinase activ-
ity in immunoprecipitates of c-Src from hepatocyte
lysates, which was inhibited by CGP77675, but so far
we have not found any significant increase of this
kinase activity after EGF stimulation (data not shown).
The data support the notion that although c-Src tyrosine
kinase activity is required for EGF-induced Stat5b
activation, this might reflect a cooperation between c-
Src and the EGF receptor and not necessarily c-Src
activation as a direct downstream effect of the EGF
receptor (Biscardi et al., 1999; Abram and Courtneidge,
2000; Reddy et al., 2000; Garcia et al., 2001).
The present results do not support a role of Stat5b
in the mitogenic action of EGF in hepatocytes. Stat5
proteins have been implicated in stimulation of cell
growth, inhibition of apoptosis, and oncogenic develop-
ment in certain other cells (Bowman et al., 2000). Among
the targets of Stat5a and Stat5b are the genes of cyclin
D1, p21waf1/cip1, c-Fos, and c-Myc (Quelle et al., 1996;
Matsumura et al., 1997, 1999). At the time of seeding,
most of the hepatocytes are in the early G1 phase of the
cell cycle (Christoffersen et al., 2000). During culturing,
the hepatocytes progress to a restriction point in mid/
late-G1 where they become highly responsive to mito-
genic stimulation by EGF (Sand and Christoffersen,
1987; Wollenberg et al., 1989; Guren et al., 1996; Loyer
et al., 1996; Talarmin et al., 1999; Christoffersen et al.,
2000). In these cells, the EGF-induced activation of
Stat5b was completely downregulated, but EGF readily
elicited tyrosine phosphorylation of the EGF receptor
and of the adapter protein Shc and induced activation of
ERK. We have also observed that under these conditions
Fig. 5. Selective, time-dependent downregulation of EGF-inducible
Stat5b activation in cultured hepatocytes. Hepatocytes were cultured
at a density of 20,000 cells/cm2.A: Nuclear extracts from cells cultured
for 24 h and stimulated with EGF (100 nM), PRL (1 mM), or GH
(100 nM) for the time indicated were subjected to EMSA, using a 32P-
end labeled PIE as probe. The free probe is not shown. B: Hepatocytes
cultured for 24 h were stimulated with EGF (100 nM) for 15 min and
harvested. The lysates were immunoprecipitated with Stat5b anti-
bodies (Kirken et al., 1997) and tyrosine phosphorylation was first
detected by an antibody recognizing Stat5b phosphorylated on Tyr-
699 (pY699). The membranes were stripped and first reprobed with a
general phosphotyrosine antibody (RC-20), stripped again before
being reprobed with a specific Stat5b antibody. C: Nuclear extracts
from cells (cultured for 3 or 24 h) that had been stimulated with GH
(100 nM) alone or in combination with EGF (10 nM) for 15 min were
subjected to EMSA, using a 32P-end labeled PIE as probe. The free
probe is not shown. D: Hepatocytes were cultured for 24 h and
stimulated with EGF (10 nM) for the time indicated. EGF receptor was
immunoprecipitated from whole-cell lysates using polyclonal EGF
receptor antibodies. Tyrosine phosphorylation (pY) was detected in
Western blots by the 4G10 phosphotyrosine antibody. The membranes
were stripped and reprobed with an EGF receptor antibody. E:
Hepatocytes were cultured for 3 or 24 h and stimulated with EGF
(10 nM) for the time indicated. Shc proteins were immunoprecipitated
with the phosphotyrosine antibody PY-99 under denaturating condi-
tions from whole-cell lysates. Shc proteins were detected in Western
blots using antibodies recognizing the three forms of Shc (p46/Shc,
p52/Shc, and p66/Shc). F: Hepatocytes were cultured for 3 or 24 h and
stimulated with EGF (10 nM) for the time indicated. Whole-cell
lysates were separated on 12% SDS–PAGE, transferred to nitrocellu-
lose membranes, and probed with antibodies against double phos-
phorylated (active) ERK.
Fig. 6. Lack of effect of GH on hepatocyte DNA synthesis. Hepato-
cytes were cultured at 20,000 cells/cm2. GH was added at 3 or 24 h
after hepatocyte plating. 3H-thymidine incorporated into DNA was
assessed from 24 to 65 h after plating in absence (open symbols) or
presence of 10 nM EGF (added at 24 h, filled symbols). Data are
meanSEM of triplicates cultures in a typical experiment.
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EGF stimulation results in activation of the p38 and
JNK subtypes of MAP kinases, as well as PI 3-kinase,
and pharmacologic blockade of ERK, p38, or PI 3-kinase
inhibits EGF-induced DNA synthesis (Thoresen et al.,
2003). Supplementation of the EGF stimulation with a
strong (GH- or PRL-induced) Stat5b activation did not
enhance the DNA synthesis. Furthermore, when hepa-
tocytes were plated at a high density, they became
unresponsive to mitogenic stimulation with EGF, but
in these cultures the mechanism of EGF receptor-
mediated activation of Stat5b was sustained. Together
these results suggest that Stat5b is not a part of the
mitogenic signal from the activated EGF receptor in the
hepatocytes.
It was recently reported that Stat5b, like Stat3, may
potentiate v-Src-mediated transformation by stimulat-
ing quiescent (G0) NIH 3T3 cells to enter the G1 phase
(Kazansky and Rosen, 2001). In our experiments, GH-
induced activation of Stat5b in hepatocytes at 3 h of
culturing did not influence the DNA synthesis by itself,
neither did it enhance the mitogenic effect of EGF in
mid/late G1 cells. These results do not support a
promitogenic role of Stat5b activation in early G1 in
the cultured hepatocytes, in contrast to other mechan-
isms such as protein kinase C-mediated signals that
accelerate traverse through early G1 and increase the
response to EGF (Dajani et al., 1999; Christoffersen
et al., 2000).
In some cells, Stat5 proteins appear to have an anti-
apoptotic effect (Sillaber et al., 2000), apparently by
regulation of Bcl-XL gene expression (Socolovsky et al.,
1999; Gesbert and Griffin, 2000). An increased amount
of Stat5 activity has been reported in breast cancer cells
(Watson and Miller, 1995) and it has been suggested
that Stat5a is a survival factor for mammary glands that
may participate in tumorigenesis (Humphreys and
Hennighausen, 1999). In mouse hepatocytes, EGF in-
duces transcription and protein expression of Bcl-XL,
but the activating mechanism is not clear (Musallam
et al., 2001). Whether or not Stat5b proteins are involved
in this mechanism requires further examination. Pre-
liminary experiments from our laboratory have so far
not shown an EGF-induced expression ofBcl-XL orBcl-2
in cultured rat hepatocytes.
The specific Tyr-699 phosphorylation and activation
of Stat5b elicited by EGF was of lower magnitude than
the effects of GH and PRL. There was also a lower
sensitivity for EGF-induced activation of STAT pro-
teins (ED50¼10 nM) compared to other effects of EGF,
such as stimulation of ERK and of DNA synthesis
(ED50¼ 1 nM, see e.g., Thoresen et al., 1998). Thus, a
strong tyrosine phosphorylation of Stat5b seems to
require a high concentration of EGF or, as recently
published, overexpression of EGF receptors (Kloth et al.,
2002). It is conceivable that differential sensitivity of
EGF receptor responses may represent a determinant
of specificity in the EGF receptor signal transduction,
depending on the cellular context. The majority of EGF
receptor ligands generally act over short distances as
autocrine or paracrine growth factors (Olayioye et al.,
2000).
Reports from hepatocytes and hepatocyte-related
models have suggested that STAT proteins, including
Stat5, are involved in functions associated with a high
degree of cell differentiation (Runge et al., 1998; Wang
et al., 1999), in analogy with the role of Stat5 in mam-
mary gland development and lactogenesis (Miyoshi
et al., 2001).
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G Protein-Coupled Receptor Agonist-Stimulated
Expression of ATF3/LRF-1 and c-myc and
Comitogenic Effects in Hepatocytes do not
Require EGF Receptor Transactivation
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DAGNY SANDNES,1 AND THORALF CHRISTOFFERSEN1
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Several agonists acting on G protein-coupled receptors (GPCR) enhance the
mitogenic effect of epidermal growth factor (EGF) in rat hepatocytes, through
mechanisms that have only partially been clarified. Results in various cells have led
to the idea that amajormechanism forGPCR-mediated stimulation of cell growth is
transactivation of receptor tyrosine kinases, particularly the EGF receptor (EGFR),
leading to rapid phosphorylation of the EGFR and activation of downstream
signaling pathways. In the present study cultured rat hepatocytes were exposed to
various GPCR agonists, including vasopressin, angiotensin II (Ang.II), norepinephr-
ine, or prostaglandin F2a (PGF2a). None of these agents increased the phosphoryla-
tion of the EGFRor the docking protein Shc. Furthermore,we examined the effect of
the GPCR agonists on the expression of two early response genes believed to be
involved in growth activation. The GPCR agonists increased the mRNA expression
of c-myc, and also of activating transcription factor 3 (ATF3)/liver regeneration
factor-1 (LRF-1), which is a novel finding. Finally, the selective EGFR inhibitor
AG1478 did not suppress the activation of extracellular signal-regulated kinase 1/2
(ERK1/2) or the induction of c-myc or ATF3/LRF-1 by the GPCR agonists, and did
not prevent the comitogenic effects induced by these agents, while it blocked the
effect of EGF on these responses. The results suggest that GPCR agonists induce
expression of ATF3/LRF-1 and c-myc and exert comitogenic effects through
mechanisms that do not require EGFR transactivation. J. Cell. Physiol. 201: 349–
358, 2004.  2004 Wiley-Liss, Inc.
G protein-coupled receptors (GPCRs) can mediate
enhancement of growth in various cell types (van Biesen
et al., 1996; Dhanasekaran et al., 1998). In hepatocytes,
GPCR agonists are only weakly mitogenic alone, but a
number of these agents are able to enhance the effect of
mitogens such as epidermal growth factor (EGF) and
hence have been termed comitogens (Michalopoulos,
1990). While the mitogenic effect of EGF and other
receptor tyrosine kinase (RTK)-activating growth fac-
tors is exerted in the mid/late G1 phase in cultured rat
hepatocytes (Sand and Christoffersen, 1987; Christof-
fersen et al., 2000) and is required for further progres-
sion and S phase entry (Loyer et al., 1996; Talarmin
et al., 1999), comitogenic stimulation by GPCR agonists
in these cells is exerted primarily in early G1 and results
in acceleration of the traverse through the first part of
G1 (Thoresen et al., 1990; Refsnes et al., 1992; Dajani
et al., 1996; Christoffersen et al., 2000). There is
evidence suggesting that multiple mechanisms, invol-
ving different G proteins and downstream pathways,
may participate in conveying the comitogenic signals
(Christoffersen et al., 2000). Unlike mitogenic signaling
via the EGF receptor (EGFR), comitogenic GPCR-
mediated stimulation appears to be independent of
activation of extracellular signal-regulated kinase
(ERK) in the hepatocytes (Nilssen et al., 2002). Some
GPCR agonists have also been found to induce the
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expression in the hepatocytes of certain early re-
sponse genes that have a role in transcription programs
necessary for cell growth, such as c-fos, c-mos, and c-myc
(Gonzalez-Espinosa and Garcia-Sainz, 1992). However,
the exact mechanisms of the growth-promoting effects of
GPCR agonists and how they differ from RTK-mediated
mitogenic signaling are not clarified.
One idea that currently is widely advocated is that a
major mechanism for GPCR-mediated stimulation of
cell growth is transactivation of RTKs (particularly of
the EGFR), in terms of a detectable increase in RTK
phosphorylation, and activation of downstream signal-
ing molecules shortly after stimulation with GPCR
agonists (Eguchi and Inagami, 2000; Prenzel et al.,
2000; Gschwind et al., 2001). Support for this hypothesis
comes from observations in cell models where several
GPCR agonists have been found to elicit rapid EGFR
phosphorylation (Daub et al., 1996; Eguchi et al., 1998;
Pai et al., 2002) and activation of downstream signaling
pathways, including association of the adaptor proteins
Shc and Grb2 with the EGFR (Luttrell et al., 1997;
Eguchi et al., 1998; Shah and Catt, 2002). Furthermore,
by the use of selective EGFR kinase inhibitors, or
overexpression of a dominant negative EGFR mutant,
ERK activity and DNA synthesis in response to GPCR
ligands can be suppressed (Daub et al., 1996; Eguchi
et al., 1998; Santiskulvong et al., 2001; Chiu et al., 2002;
Kodama et al., 2002; Pai et al., 2002). Although the
underlying mechanisms are not fully defined, intracel-
lular signals involving Ca2þ, protein kinase C (PKC),
and the nonreceptor intracellular tyrosine kinases Src
and Pyk2, have been implicated as early intermediates
in the EGFR transactivation pathway (Eguchi et al.,
1998, 1999; Luttrell et al., 1999; Keely et al., 2000;
Andreev et al., 2001), and there are also data suggesting
a role of metalloproteinase-mediated cleavage of proHB-
EGF (Prenzel et al., 1999).
The aim of the present study was to investigate the
role of EGFR transactivation in the signaling mechan-
isms for GPCR agonists that act as comitogens in rat
hepatocytes. We also examined the expression of two
early response genes, c-myc, which is believed to be
required for growth activation (Pelengaris et al., 2002),
and ATF3 (‘activating transcription factor 3,’ also
termed LRF-1, ‘liver regeneration factor-1’), which is a
member of the bZIP superfamily of transcription factors.
ATF3 was shown more than a decade ago to be highly
expressed in regenerating liver (Hsu et al., 1991), and
has more recently been found to have a role in induction
of DNA synthesis in mouse hepatoma cells (Allan et al.,
2001), and in proliferation and partial transformation
in chick embryo fibroblasts (Perez et al., 2001). In the
study described here we found that several GPCR
agonists, including prostaglandin F2a (PGF2a), vaso-
pressin, angiotensin II (Ang.II), and norepinephrine,
all of which enhance the effect of EGF on the DNA
synthesis, induced the expression of c-myc and ATF3.
Under the same conditions, no effect of any of these
agents was observed on EGFR phosphorylation or early
downstream responses. Furthermore, neither the
induction of c-myc and ATF3, nor the comitogenic effect
or the ERK activity induced by the above GPCR agonists
was prevented by the use of an EGFR kinase inhibitor.
The results suggest that EGFR transactivation is not
required in stimulation of ERK activity, induction of
potentially growth-related gene expression, or promo-
tion of DNA synthesis in response to GPCR agonists in
hepatocytes.
MATERIALS AND METHODS
Materials
Dulbecco’s modified Eagle’s medium, Dulbecco’s
phosphate-buffered saline, HEPES, penicillin, and
streptomycin were from Gibco (Grand Island, NY).
William’s medium E was from Whittaker (Walkersville,
MD). Norepinephrine hydrogen tartrate, timolol maleate,
[Arg8]vasopressin, Ang.II, PGF2a, collagenase (C-0130),
dexamethasone, EGF (from mouse), insulin, fatty acid-
free bovine serum albumin (BSA) (fraction V), collagen
(type I from rat tail), and myelin basic protein (MBP)
were obtained from Sigma Chemical Co. (St. Louis, MO).
AG1478 was from Calbiochem (La Jolla, CA). [6-3H]
thymidine (20–30 Ci/mmol), [g-32P] adenosine 50-tripho-
sphate (3,000 Ci/mmol), and [a-32P]dCTP (3,000 Ci/mmol)
were from Amersham International (Buckinghamshire,
UK). All other chemicals were of analytical quality.
Cell isolation and culture
Male Wistar rats, 170–230 g, were fed ad libitum.
Hepatocytes were isolated by a two-step in vitro version
(Seglen, 1976) of the collagenase perfusion technique
(Berry and Friend, 1969) with modifications as pre-
viously described (Christoffersen et al., 1984). The hepa-
tocytes were seeded onto Costar plastic culture wells
or flasks, at a cell density of 2 104/cm2. The culture
medium was a serum-free 1:1 combination of William’s
medium E and Dulbecco’s modified Eagle’s medium
(with final glucose concentration 8.4 mM). The medium
was supplemented with penicillin (67 mg/ml), strepto-
mycin (100 mg/ml), collagen (3 mg/ml), insulin (100 nM),
and dexamethasone (25 nM). The cultures were kept in
95% air/5% CO2 at 378C.
Stimulation of hepatocytes and pre-treatment with
the EGFR tyrosine kinase inhibitor AG1478
For estimation of the comitogenic effect of the GPCR
agonists, cells were cultured for 3 h before stimulation
with GPCR agonists as indicated. In these experiments
EGF (5 nM) and [3H] thymidine (1 mCi/ml, 0.125 Ci/
mmol) were added to the cultures 24 h after plating. In
studies of the mitogenic effect of EGF alone, hepatocytes
were grown for 24 h prior to addition of EGF and [3H]
thymidine. In both cases, cells were harvested after 50 h.
In studies of the effect of GPCR agonists on DNA
synthesis, DMSO (0.5%) or AG1478 (5mM) was added 3 h
after plating, and the cells stimulated 30 min later.
Due to rapid degradation of AG1478, cells were treated
with AG1478 (5 mM) a second time, 5 h after the first
addition (maximum DMSO conc. 1%). When cells were
stimulated with EGF alone an identical pre-treatment
with DMSO or AG1478 was performed 30 min before
stimulation (24 h after plating), and the inhibitor was
added again 5 h after the first addition of AG1478
(maximum DMSO conc. 1%). Hepatocytes prepared for
Northern blot analysis were cultured for 4.5 h, pre-
treated with DMSO (0.5%) or AG1478 (5 mM) for 30 min,
and then stimulated for 1 h with GPCR agonists or EGF
as indicated.
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Immunoblotting
Hepatocytes were exposed to GPCR agonists for the
indicated time periods after 3 h of culturing. Aliquots
with 20 mg cell protein (total cell lysate prepared in
Laemmli buffer) were electrophoresed on 10% (w/v)
polyacrylamide gels (acrylamide:N0N0-bis-methylene
acrylamide 30:0.8) followed by immunoblotting with
a phospho-specific MAP kinase antibody detecting
p44mapk and p42mapk (ERK1 and 2) only when catalyti-
cally activated by phosphorylation at Tyr204 or Thr202/
Tyr204, (New England Biolabs, Inc., Beverly, MA).
Immunoreactive bands were visualized with Bio West
Extended Duration Chemiluminescent Substrate (UVP,
Inc., Upland, CA).
Immunoprecipitation (IP)
Analysis of EGFR phosphorylation was based on a
method described previously (Yamashita et al., 1998).
After agonist stimulation 3 h after plating, the cells were
rapidly rinsed twice in ice cold 0.9% NaCl, and once in IP
buffer A (50 mM Tris-HCl, pH 7.4, 280 mM NaCl, 0.2 mM
EDTA, 2.0 mM EGTA, 10% glycerol, 1 mM activated
Na3VO4, 50 mM Na4P2O7, 1 mM phenylmetylsulfonyl
fluoride (PMSF), and Complete protease inhibitor
(Boehringer Mannheim, Germany)). Cells were lysed
in 1 ml IP buffer A, supplied with Nonidet P-40 (NP-40)
to a final concentration of 1%, for 15 min on ice and the
lysates were transferred into Eppendorf tubes. Insolu-
ble material was pelleted at 13,000 rpm for 10 min at
48C. Clarified lysates (approximately 250 mg protein)
were incubated for 60 min with polyclonal EGFR
antibody (SC-03,SantaCruzBiotechnology, SantaCruz,
CA) and the complexes were captured with Dynabeads1
(Dynal AS, Oslo, Norway), coated with sheep anti-rabbit
antibodies (a gift from Dr. Kjell Nustad, The Norwegian
Radium Hospital, Oslo, Norway). Complexes were
washed with IP buffer A with 0.5% NP-40.
Shc and Pyk2 proteins were immunoprecipitated
under denaturating conditions. After agonist stimula-
tion 3 h after plating, the cells were lysed inn 500 ml
boiling lysis buffer (10 mM Tris-HCl, pH 7.4, 1% SDS, 1
mM Na3VO4), then the lysates were boiled for 5 min.
After five passages through a 27 G gauge on ice, the
lysates were cleared by centrifugation (10 min,
13,000 rpm at 48C). 250 mg (Shc analysis) or 500 mg
(Pyk2 analysis) protein was incubated 2 h in IP-buffer B
(10 mM Tris-HCl, pH 7.4, 0.15 M NaCl, 1 mM EDTA,
1 mM EGTA, 0.2 mM Na3VO4, 0.2 mM PMSF, 0.5% NP-
40, and 1% Triton-X100) with phosphotyrosine antibody
(PY-99, Santa Cruz Biotechnology). The immune com-
plexes were captured with Dynabeads1, coated with
sheep anti-mouse IgG. Complexes were washed with
ice-cold IP-buffer B.
The proteins were released from the Dynabeads1 by
boiling for 5 min in 2 Laemmli sample buffer.
Immunoprecipitates were separated in 8–12% SDS–
PAGE gels as described, depending on protein weight,
and transferred to nitrocellulose membranes. The
membranes were either blocked in T-TBS (10 mM
Tris-HCl, pH 8.0, 150 mM NaCl) with 5% low fat dry-
milk and 0.05% Tween-20, or T-TBS with 1% BSA for
detection with RC-20: direct horseradish peroxidase
(HRPO) conjugated phosphotyrosine antibody. Mem-
branes were then incubated overnight at 48C with
appropriate primary antibodies, RC-20 phosphotyro-
sine antibody, monoclonal Pyk2 antibody (both from
Transduction Laboratories, Lexington, KY), 4g10 phos-
photyrosine antibody, or polyclonal anti-Shc (both from
Upstate Biotechnology, Lake Placid, NY). Membranes
were further incubated with secondary antibody, HRPO
conjugated sheep anti-rabbit or sheep anti-mouse, de-
pendingontheprimaryantibody, inblockingsolution for
1.5 h. The blots were visualized with Enzyme-linked
Chemiluminesence Reagent (ECL, Amersham Pharma-
cia Biotech, Buckinghamshire, UK), or Bio West Extend-
ed Duration Chemiluminescent Substrate (UVP, Inc.).
Measurement of ERK activity
The measurement of ERK1/2 activity was performed
as previously described (Anderson et al., 1991; Melien
et al., 1998; Thoresen et al., 1998). In brief, the hepa-
tocyte cultures were exposed to agonists for 5 min before
rinsing and scraping the cells into a 10% ethylene glycol
buffer. The lysate was precleared by centrifugation
(16,000g) for 10 min, and the supernatant was mixed
with phenyl-Sepharose which was washed twice in a
10%, twice in a 35% ethylene glycol buffer, and finally
ERK1/2 was eluted with a 60% ethylene glycol buffer.
The eluate was assayed for ERK1/2 activity with MBP as
substrate, thereafter spotted onto P81 paper (Whatman,
Maidstone, UK), which was washed, dried, and counted
in a liquid scintillation counter.
RNA extraction and Northern blot analysis
RNA was isolated by acid guanidium thiocyanate-
phenol-chloroform extraction according to the proce-
dure described by Chomczynski and Sacchi (1987) and
modified by Houge et al. (1990). Ten microgram of total
RNA was electrophoresed in 1.5% agarose gel in the
presence of 6.6% formaldehyde. The RNA was trans-
ferred to Biotrans nylon membranes, UV exposed for
1 min and baked for 1 h at 808C. The filters were
prehybridized overnight in 50% formamide, 5 Den-
hardt’s solution, 6 SSC, and 1% SDS at 428C, and
hybridized overnight in the same solution. The probes
[a 1.9 kbEcoR1 fragment of rat ATF3/LRF-1 (Hsu et al.,
1991) and a 1.4 kb BamHI fragment of mouse c-myc
cDNA (Land et al., 1983)] was 32P-dCTP labeled by
random priming (Rediprime II DNA Labeling System,
Amersham Biosciences, Buckinghamshire, UK). After
hybridization the filters were washed 4-times in 2SSC/
0.1% SDS at 258C for 5 min and twice in 0.1 SSC/0.1%
SDS at 508C for 30 min. The hybridized bands were
visualized and analyzed by Instant Imager Electronic
Autoradiography (Packard Instrument Company,
Meridan, CT), and by autoradiography.
Other methods
DNA synthesis was measured by determining the
amount of [3H] thymidine incorporated into DNA
(Refsnes et al., 1994). Protein was determined with the
BCA Protein Assay (Pierce, Rockford, IL).
RESULTS
GPCR agonists, unlike EGF, activate Pyk2
A role for Pyk2, through interaction with c-Src, has
been suggested in the EGFR transactivation pathway
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from GPCRs (Eguchi et al., 1999; Keely et al., 2000;
Andreev et al., 2001). IP of tyrosine phosphorylated
proteins showed that Ang.II, vasopressin, PGF2a, and
norepinephrine induced a rapid increase in tyrosine
phosphorylation of Pyk2. As demonstrated with vaso-
pressin, the response was sustained for at least 30 min
(Fig. 1A). Treatment of cells with Ang.II, PGF2a, or
norepinephrineresultedinsimilartimecourses(datanot
shown); phosphorylation after 5 min of stimulation is
demonstrated in Figure 1B. In contrast, 5 min stimula-
tion with EGF did not induce any increase in the level of
Pyk2 phosphorylation (Fig. 1B). Although the precise
role of Pyk2 has not been examined, these novel results
suggest that activated Pyk2 might be a part of the
pathways downstream of GPCRs in hepatocytes.
EGFR is not phosphorylated after
stimulation with GPCR agonists
To search for evidence of transactivation, we mea-
sured EGFR tyrosine phosphorylation after IP in cells
exposed to Ang.II, vasopressin, PGF2a, or norepinephr-
ine. Since ERK activity induced by these agents in rat
hepatocytes is known to peak within 3–5 min (Melien
et al., 1998), any EGFR transactivation involved in the
stimulation of ERK was expected to appear rapidly.
However, as shown in Figure 2A, after stimulation for 1
or 5 min, none of the GPCR agonists tested induced any
increase in the level of EGFR phosphorylation, com-
pared to basal. EGFR phosphorylation levels were also
determined in cultures stimulated for several hours.
As shown in Figure 2B, there was no evidence of
increased phosphorylation levels after stimulation with
norepinephrine for up to 5 h. Similar results were
obtained in hepatocytes stimulated with Ang.II (data
not shown). Thus, although the above results suggest a
possible role for Pyk2 in signaling from GPCRs in rat
hepatocytes, increase in the phosphorylation status of
the EGFR does not appear to precede the ERK activity
induced by norepinephrine, vasopressin, Ang.II, or
PGF2a, or take place up to 5 h after addition of agonist.
Shc is not activated by GPCR agonists
in cultured rat hepatocytes
The adaptor protein Shc is known to be tyrosine-
phosphorylated by activation of many different recep-
tors, among them RTKs and GPCRs (Ravichandran,
2001). We used Shc phosphorylation as an alternative
approach to detect EGFR involvement in signaling from
GPCR in rat hepatocytes. The hepatocytes were stimu-
lated with GPCR agonists for up to 60 min prior to IP of
tyrosine-phosphorylated proteins and detection of Shc
after SDS–PAGE. As demonstrated with norepinephr-
ine and PGF2a (Fig. 3), the experiments provided no
evidence of increased Shc phosphorylation. Experi-
ments with vasopressin and Ang.II gave similar results
(data not shown). In contrast, EGF induced significant
phosphorylation of two Shc isoforms (p46 and p52).
These results did not support the idea of EGFR trans-
activation being involved in short time effects of GPCR
agonists.
Activation of ERK in response to GPCR
agonists is not impaired by the EGFR
tyrosine kinase inhibitor AG1478
To further examine the role of the EGFR in GPCR-
mediated mechanisms, we tested the effect of AG1478, a
specific EGFR tyrosine kinase inhibitor, on ERK activity
induced by GPCR agonists. As shown in Figure 4A, a
30 min preincubation with 5 mM AG1478 completely
abolished phosphorylation of ERK1/2 subsequent to
stimulation with EGF. Next, the effect of 5 mM AG1478
on ERK activity induced by ligands acting on GPCRs
was tested in an ERK activity assay with MBP as
substrate. The data obtained showed that ERK activity
induced by vasopressin, Ang.II, PGF2a, or norepinephr-
ine,wasnot reduced inhepatocytespretreated with5mM
AG1478. In contrast, AG1478 reduced the EGF stimu-
lated ERK activity to basal level (Fig. 4B). The effect of
AG1478 on activation of ERK was confirmed in Western
blots with an antibody against double phosphorylated
ERK1/2 (Fig. 4C).
Comitogenic effect of GPCR agonists
is not prevented by AG1478
Because comitogenic effects in cultured rat hepato-
cytes are exerted primarily in the early G1 phase (0–10 h
after plating) and the cells become responsive to the
mitogenic effect of EGF in mid/late G1 (Christoffersen
et al., 2000), we examined the role of EGFR function in
GPCR-mediated growth stimulation by treating the
cells with AG1478 in early G1. These experiments
necessitate careful control of dose and timing, since
they depend on EGFR inhibition for 5–10 h after
administration of the GPCR agonist but also require
that EGFR functionality is fully restored prior to the
subsequent addition of EGF in mid-G1 (24 h in these
experiments). As demonstrated above, AG1478 in-
hibited EGF-induced ERK phosphorylation completely
at 5 mM (Fig. 4A), however, the effect of AG1478 was
gradually reversed within approximately 4 h (data not
shown), and readdition of the inhibitor after 5 h (8 h
after plating) was necessary. Experiments showed that
when the hepatocytes were treated with AG1478 twice
at 24 and 29 h, as illustrated in the protocol scheme in
Fig. 1. Activation of Pyk2 by G protein-coupled receptor (GPCR)
agonists. Pyk2 activity was detected by immunoprecipitation (IP)
with a phosphotyrosine antibody and immunoblot analysis with
an antibody against Pyk2. A: Hepatocytes were cultured for 3 h
before stimulation with 1 mM vasopressin. Results represent one
typical experiment. B: Hepatocytes were cultured for 3 h before
stimulation for 5 min with 1 mM angiotensin II (Ang.II), 100 mM
prostaglandin F2a (PGF2a), 100 mM norepinephrine (NE) (in the
presence of timolol), or 10 nM epidermal growth factor (EGF). Results
represent one typical experiment.
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Figure 5A, the mitogenic effect of EGF was completely
inhibited (Fig. 5B).
Treatment of the cells with AG1478 early in G1 did not
suppress the comitogenic effects of the GPCR agonists
(Fig. 6B). However, a slight reduction of the comitogenic
effect was noted in some of the experiments conducted
with norepinephrine (Fig. 6B). We have no clear ex-
planation for this observation. One possibility is that
different GPCR agonists might exert their comitogenic
effects through partially different pathways, and that
signaling from a1-adrenergic receptors is different than
signaling from the other GPCRs. On the other hand,
more detailed studies on residual effects of AG1478
suggest that in some cases, a partial inhibition of EGFR
by AG1478 can persist until the time of EGF adminis-
tration (data not shown). However, no reduction in EGF-
induced ERK activity was seen in cells treated by the
same protocol (Fig. 6C). One possible explanation for
the contradiction could be that ERK as detected by
Fig. 2. The EGF receptor (EGFR) is not phosphorylated upon stimulation with GPCR agonists.
EGFR phosphorylation was detected by IP with an EGFR antibody and immunoblot analysis with
a phosphotyrosine antibody. Hepatocytes were cultured for 3 h before stimulation with 100 mM
norepinephrine (NE) (in the presence of timolol), 1 mM vasopressin (Vaso.), 1 mM Ang.II, 100 mM PGF2a, or
10 nM EGF, as indicated. Results represent one typical experiment.
Fig. 3. Shc is not activated by GPCR agonists. Shc activity was
detected by IP with a phosphotyrosine antibody and immunoblot
analysis with an antibody recognizing the 46, 52, and 66 kDa Shc
proteins. Hepatocytes were cultured for 3 h before stimulation with
100 mM norepinephrine (NE) (in the presence of timolol), 100 mM
PGF2a, or 10 nM EGF. Results represent one typical experiment.
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immunoblotting is less sensitive than DNA synthesis to
detect a small residual effect of AG1478. Taken together,
the results are compatible with comitogenic mechan-
isms that are independent of EGFR transactivation.
GPCR agonists induce the expression
of mRNAs for c-myc and ATF3
independently of EGFR function
It is likely that growth-promoting pathways from
GPCRs activate a set of critical early response genes,
and it is of interest to identify such genes and to decide
whether or not their expression is induced through
mechanisms of EGFR transactivation. It has been found
that certain GPCR agonists increase the expression of
the proto-oncogenes c-fos, c-myc, and c-mos in isolated
rat hepatocytes (Gonzalez-Espinosa and Garcia-Sainz,
1992). For the present studies we have chosen c-myc,
which seems to be required for the growth response
(Pelengaris et al., 2002), and ATF3, which has been
implicated in growth-stimulatory mechanisms in cer-
tain cells and whose expression is increased in regener-
ating liver (Weir et al., 1994).
Northern analysis demonstrated increased expres-
sion of c-myc mRNA in hepatocytes stimulated for 1 h
with vasopressin, Ang.II, norepinephrine, and PGF2a
(Fig. 7B). Furthermore, markedly increased levels of
mRNA for ATF3 were observed in hepatocytes stimu-
lated with the same agonists, which is a novel finding
(Fig. 7C). The response decreased to near control levels
within 4 h after stimulation, as shown for vasopressin
in Figure 7A. The effect of inhibiting EGFR kinase
activity was examined, using the EGFR kinase inhibitor
AG1478. As shown in Figure 7B,C, there was no signi-
ficant reduction in the GPCR agonist-induced ex-
pression of mRNA for c-myc or ATF3 when cells were
pre-treated with AG1478 (5 mM). In contrast, the
increase in mRNA for ATF3 and c-myc induced by
EGF was totally abolished in the presence of AG1478.
Examples of typical Northern blots for c-myc and ATF3
in hepatocytes stimulated with PGF2a, Ang.II, or EGF,
in the presence or absence of AG1478, are given in
Figure 7D,E, respectively.
DISCUSSION
The results of the present study suggest that signaling
from GPCRs in rat hepatocytes, such as stimulation of
ERK activity, induction of growth-related gene expres-
sion, and comitogenic effects do not require EGFR
transactivation.
Previous studies have shown that vasopressin, nor-
epinephrine, Ang.II, and PGF2a activate ERK through
pathways that depend on calcium and PKC and that
their effects are diminished by inhibitors of the Src
kinase family (Dajani et al., 1999; Melien et al., 2002).
Fig. 4. Extracellular signal-regulated kinase (ERK) activity induced
by GPCR agonists is not impaired by the selective EGFR tyrosine
kinase inhibitor AG1478. A: ERK kinase activity was detected by
immunoblot analysis with an antibody against phosphorylated ERK1/
2. Hepatocytes were cultured for 2.5 h and pre-treated with DMSO
(0.5%), or AG1478 for 30 min before stimulation for 5 min with 10 nM
EGF. Results represent one typical experiment. B: ERK kinase
activity was detected in an in vitro kinase assay as described in
‘‘Materials and Methods.’’ Hepatocytes were cultured for 2.5 h and
pre-treated with DMSO (0.5%) or AG1478 (5 mM) for 30 min before
stimulation for 5 min with 10 nM EGF, 1 mM vasopressin (Vaso.), 1 mM
Ang.II, 100 mM PGF2a, or 50 mM norepinephrine (NE) (in the presence
of timolol). Results represent meanSEM of two separate experi-
ments, each with duplicates. C: ERK kinase activity was detected by
immunoblot analysis with an antibody against phosphorylated ERK1/
2. Hepatocytes were cultured for 2.5 h and pre-treated with DMSO
(0.5%) or AG1478 (5 mM) for 30 min before stimulation for 5 min with
10 nM EGF, 1 mM Ang.II, 1 mM vasopressin (Vaso.), 100 mM PGF2a, or
50 mM norepinephrine (NE) (in the presence of timolol). Results
represent one typical experiment.
Fig. 5. EGF-induced DNA synthesis is completely abolished by
the EGFR tyrosine kinase inhibitor AG1478. A: Protocol scheme
illustrating time points after plating for addition of AG1478 and EGF,
as well as harvesting of the cells. B: DNA synthesis was assessed as
described in ‘‘Materials and Methods.’’ Hepatocytes were cultured for
24 h and pre-treated for 30 min with DMSO (0.5%), or AG1478 (5 mM)
prior to addition of 10 nM EGF and [3H] thymidine. DMSO (0.5%), or
AG1478 (5 mM) was added a second time 29 h after plating and cells
were harvested at 54 h after plating. Results represent meanSEM of
three separate experiments.
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All these mechanisms have been implicated in transac-
tivation of the EGFR by GPCR agonists (Eguchi et al.,
1998, 1999; Luttrell et al., 1999; Keely et al., 2000;
Andreev et al., 2001). In the present study we have
examined the role of EGFR transactivation in hepato-
cytes, using different cellular responses as endpoints.
Our results indicate that EGFR phosphorylation was
not increased after stimulation with GPCR agonists,
neither was EGFR activity, in the form of Shc phosphor-
ylation, observed. Since Shc phosphorylation is also
involved in signaling from other RTKs, the data may
have the broader implication that they are not transac-
tivated either. Furthermore, there was no evidence for
a role of the EGFR in effects like stimulation of ERK
activity, or early gene expression. Furthermore, the
enhanced DNA synthesis in response to GPCR agonists
was largely unaffected by AG1478. These results, taken
together, suggest that immediate transactivation of
the EGFR is not required for the comitogenic effects of
these agents. However, we cannot exclude the possibi-
lity that stimulation with vasopressin, Ang.II, PGF2a, or
norepinephrine might lead to increased production or
release of an autocrine growth factor. For example,
expression and secretion of the EGFR ligand transform-
ing growth factor-a (TGF-a) is reported to increase
during liver regeneration (maximal mRNA levels 24 h
after hepatectomy), as well as within days after stimu-
lation of cultured hepatic cells with growth factors
(Mead and Fausto, 1989; Shiota et al., 1994). Although
accumulating evidence indicates the importance of
receptor crosstalk, it is increasingly recognized that
the contribution of EGFR transactivation to GPCR
agonist-induced responses, such as ERK activation
and cell proliferation, depends on cell type. In Rat-1
cells, bombesin induced ERK activation via an EGFR-
dependent mechanism, whereas the same agonist
promoted EGFR-independent ERK activation in Swiss
3T3 cells. Interestingly, the mitogenic effect of bombesin
in Swiss 3T3 cells was dependent on EGFR function
(Santiskulvong et al., 2001). In GN4 rat liver epithelial
cells, Ang.II has been found to stimulate ERK via two
independent pathways; a putative Ras/Raf-indepen-
dent, PKC-dependent pathway, and an EGFR/Ras/Raf-
dependent pathway observed when PKC activation is
prevented (Li et al., 1998).
The mechanisms involved in the comitogenic effect
of GPCR agonists in hepatocytes are incompletely
understood. In previous studies we found evidence that
sustained accumulation of diacylglycerol (DAG), with
activation of PKC, is involved in the growth-promoting
effects of vasopressin, Ang.II, and norepinephrine
(Dajani et al., 1999). Furthermore, while ERK activity
is essential for the mitogenic effect of EGF in hepato-
cytes (Talarmin et al., 1999; Thoresen et al., 2003), we
recently found that the comitogenic effect of vasopres-
sin, norepinephrine, Ang.II, and PGF2a is independent
of ERK activity (Nilssen et al., 2002). In vascular smooth
muscle cells, a role for Pyk2 in increased expression of
c-fos induced by Ang.II has been proposed (Rocic et al.,
2002), suggesting that this calcium-sensitive tyrosine
kinase might be a mediator in the growth-promoting
effects of calcium-mobilizing agents. Our results demon-
strate evidence of GPCR agonist-induced Pyk2 activity
under circumstances where transactivation does not
appear to take place. Thus, it is possible that Pyk2 has a
different role in signaling from GPCRs in hepatocytes,
although at present we do not have any conclusive data
on this topic.
The presence of growth-promoting humoral factors
during G1 results in a number of cellular events, in-
cluding gene expression and phosphorylation of proteins
involved in early cell cycle progression (Sherr, 1996).
We examined the expression of the two early response
genes c-myc and ATF3 in cells exposed to EGF, vaso-
pressin, Ang.II, PGF2a, or norepinephrine. ATF3 mRNA
is barely detectable in normal rat liver, but is dramati-
cally induced upon hepatectomy (Weir et al., 1994). For
instance, ATF3 has been shown to induce DNA synth-
esis in mouse hepatoma cells and proliferation in chick
embryo fibroblasts (Allan et al., 2001; Perez et al., 2001),
and ATF3 antisense oligonucleotide is reported to exert
inhibitory effect on ectopic growth of human colon
cancer cells (Ishiguro et al., 2000). Furthermore, rapid
induction of mRNA for ATF3, jun-B, c-fos as well as
Fig. 6. The comitogenic effect of GPCR agonists is largely not
affected by the EGFR tyrosine kinase inhibitor AG1478. A: Protocol
scheme illustrating time points after plating for addition of AG1478,
GPCR agonists, and EGF as well as harvesting of the cells. B: DNA
synthesis was assessed as described in ‘‘Materials and Methods.’’
Hepatocytes were cultured for 3 h and pre-treated for 30 min with
DMSO (0.5%), or AG1478 (5 mM) prior to addition of 1 mM Ang.II,
100 mM PGF2a, 1 mM vasopressin (Vaso.), or 50 mM norepinephrine
(NE) (in the presence of timolol). DMSO (0.5%), or AG1478 (5 mM) was
added a second time 8 h after plating, and 5 nM EGF and [3H]
thymidine were added at 24 h. Cells were harvested 50 h after plating.
Results represent meanSEM of six to seven separate experiments.
C: ERK kinase activity was detected by immunoblot analysis with an
antibody against phosphorylated ERK1/2. Hepatocytes were treated
with DMSO (0.5%) or AG1478 (5 mM) at 3 and 8 h after plating, and
stimulated for 5 min with 10 nM EGF at 24 h after plating. Results
represent one typical experiment.
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c-myc protein has been reported in cultured hepatocytes
stimulated with various growth factors or hormonal
agents (Weir et al., 1994; Skouteris and Schroder, 1996).
Ang.II, vasopressin, epinephrine, and the phorbol ester
PMA have been shown to increase the expression of
the proto-oncogenes c-fos, c-myc, and c-mos in isolated
rat hepatocytes (Gonzalez-Espinosa and Garcia-Sainz,
1992). Thus, a possible mechanism involved in the
comitogenic effect of GPCR agonists might be expres-
sion of genes necessary for progression of hepatocytes
through the cell cycle.
In agreement with previous studies, our results
showed that expression of both genes was enhanced
in cells treated with EGF (Skouteris and Kaser, 1991;
Weir et al., 1994). All the GPCR agonists also induced
increased expression of mRNAs for c-myc. In addition
we made the novel observation of marked increase
in expression of ATF3 mRNA in response to GPCR
agonists. Thus, a role for these genes in the growth
promoting effects of the comitogenic agents is con-
ceivable. The present results also suggest that this
gene expression is exerted independently of EGFR
transactivation.
In conclusion, the results of the present study demon-
strate increased levels of ATF3 mRNA in hepatocytes in
response to activation of GPCRs, introducing early gene
expression as a possible mechanism in the comitogenic
effect of these agents. Furthermore, EGFR transactiva-
tion is not required in signaling pathways from GPCRs
in hepatocytes, such as increased ERK activity, induc-
tion of potentially growth-related gene expression, and
most likely DNA synthesis.
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Fig. 7. GPCR agonist-induced increase in expression of mRNAs
for activating transcription factor 3 (ATF3) and c-myc is not impaired
by inhibition of EGFR function. Hepatocytes were cultured for 4.5 h
prior to stimulation with GPCR agonists. In some experiments 30 min
pre-treatment with DMSO (0.5%) or AG1478 (5 mM) was performed
before cells were stimulated with 50 mM norepinephrine (NE) (in the
presence of timolol), 100 mM PGF2a, 1 mM Ang.II, 1 mM vasopressin
(Vaso.), or 10 nM EGF for 60 min. RNA extraction and Northern blot
analysis was performed as described in ‘‘Materials and Methods.’’
A: Time course for vasopressin-induced expression of mRNA for ATF3.
Results represent one typical experiment. B: Effect of GPCR agonists
and EGF, in the presence and absence of AG1478, on the level of c-myc
mRNA. C: Effect of GPCR agonists and EGF, in the presence and
absence of AG1478, on the level of ATF3 mRNA. Results represent
meanSEM of two to three experiments with GPCR agonists, and of
five experiments with EGF. D: A typical Northern blot showing the
effect of Ang.II, PGF2a, and EGF, in the presence and absence of
AG1478, on the level of c-myc mRNA. E: A typical Northern blot
showing the effect of Ang.II, PGF2a, and EGF, in the presence and
absence of AG1478, on the level of ATF3 mRNA.
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